

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/97850 A2

- (51) International Patent Classification⁷: **A61K 45/06**
- (21) International Application Number: PCT/EP01/06976
- (22) International Filing Date: 20 June 2001 (20.06.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
00250194.8 23 June 2000 (23.06.2000) EP
00250214.4 28 June 2000 (28.06.2000) EP
- (71) Applicant: **SCHERING AKTIENGESELLSCHAFT**
[DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).
- (71) Applicants and
(72) Inventors: **SIEMEISTER, Gerhard** [DE/DE]; Reimerswalder Steig 26, 13503 Berlin (DE). **HABEREY, Martin** [DE/DE]; Steinstr. 1, 12169 Berlin (DE). **THIERAUCH, Karl-Heinz** [DE/DE]; Hochwildpfad 45, 14169 Berlin (DE).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE RECEPTOR FUNCTION AND THEIR USE (II)

(57) Abstract: The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

BEST AVAILABLE COPY



WO 01/97850 A2

**Combinations and compositions which interfere with VEGF/ VEGF and
angiopoietin/ Tie receptor function and their use (II)**

5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

10

Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their
15 receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of
20 the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PIGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an
25 orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al, Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

30

The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. *Nature* 376, 62-66, 1995), whereas Flt1
5 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during
10 early development of the cardiovascular system (Dumont et al., *Science* 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., *Science* 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce
15 neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., *Proc. Natl. Acad. Sci. USA* 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also
20 been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., *Nature* 376, 70-74, 1995; Rodewald & Sato, *Oncogene* 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and
25 lacking periendothelial support cells (Sato et al., *Nature* 376, 70-74, 1995; Dumont et al., *Genes Dev.* 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., *Science* 277, 55-60, 1997; Suri et al., *cell* 87, 1171-1180). Conversely, increased vascularization was
30 observed upon transgenic overexpression of Ang1 (Suri et al., *Science* 282, 468-471, 1998; Thurston et al., *Science* 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., *Science* 277, 55-60, 1997; Goede et al. *Lab.*

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al, Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendotherial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).

10 The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4
15 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high
20 upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2
25 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

Interference with Tie2 receptor function by means of Angiopoietin-neutralizing
30 Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-peri-endothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or
5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological
10 activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor
15 systems and of Angiopoietin/Tie receptor systems can be performed by

- (a) compounds which inhibit receptor tyrosine kinase activity,
- (b) compounds which inhibit ligand binding to receptors,
- (c) compounds which inhibit activation of intracellular signal pathways of the
20 receptors,
- (d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents
25 or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- (f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

30

A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine

kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), *Cancer Res.* 59, 99-106; Vajkoczy et al., *Proc. Am. Associ. Cancer Res. San Francisco* (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), *Cancer Res.* 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., *Proc. Am. Associ. Cancer Res., San Francisco* (2000), Abstract ID 3614; Dimitroff et al. (1999), *Invest. New Drugs* 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhuMAbVEGF) and by Presta et al. (1997), *Cancer Res.* 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), *Proc. Natl. Acad. Sci., U.S.A.* 90, 10705-10709; by Goldman et al. (1998) *Proc. Natl. Acad. Sci., U.S.A.* 95, 8795-8800 and by Lin et al. (1997), *J. Clin. Invest.* 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), *Nature* 367, 567-579.


Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), *Proc. Natl. Acad. Sci., U.S.A.* 95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), *Nat. Biotech* 14, 1021-1025. Further, small molecules and peptides have been described.

Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

Examples for delivery-/Targeting-Systems have been described as ligand/
antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59,
183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell
targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci, U.S.A94, 8795-
5 8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998),
Cancer Res. 58, 4646-4653).

10 Small molecules which inhibit the receptor tyrosine kinase activity are for example
molecules of general formula I

15



20

in which

r has the meaning of 0 to 2,


n has the meaning of 0 to 2;

25

R₃ und R₄ a) each independently from each other have the meaning
of lower alkyl,

9

b) together form a bridge of general partial formula II,




5

wherein the binding is via the two terminal C- atoms, and
has the meaning of 0 to 4; or

m

c) together form a bridge of partial formula III

10



15

wherein one or two of the ring members T_1, T_2, T_3, T_4 has the
meaning of nitrogen, and each others have the meaning of
CH, and the bining is via the atoms T_1 and T_4 ;

G

20

has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or
 $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkeny-
lene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$,
 $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$,
 $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

A, B, D, E and T

25

independently from each other have the meaning of N or CH ,
with the provisio that not more than three of these
Substituents have the meaning of N,

- Q has the meaning of lower alkyl, lower alkyloxy or halogene,
R₁ and R₂ independently from each other have the meaning of H or
lower alkyl,
- X has the meaning of imino, oxa or thia;
- 5 Y has the meaning of hydrogene, unsubstituted or substituted
aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and
- Z has the meaning of amino, mono- or disubstituted amino,
halogen, alkyl, substituted alkyl, hydroxy, etherificated or
esterificated hydroxy, nitro, cyano, carboxy, esterificated
10 carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted
carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio,
phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl,
phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl,
phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if
15 more than one rest Z is present ($m \geq 2$), the substituents Z are
equal or different from each other, and wherein the bonds
marked with an arrow are single or double bonds; or an N-
oxide of said compound, wherein one ore more N-atoms carry
an oxygene atom, or a salt thereof.

20

A preferred salt is the salt of an organic acid, especially a succinate.

These compounds can preferentially be used as compound I or II in the inventive
pharmaceutical composition.


25

Compounds which stop a tyrosin phosphorylation, or the persistent angiogenese,
respectively, which results in a prevention of tumor growth and tumor spread, are
for example

anthranil acid derivatives of general formula IV

30

11



in which

A

has the meaning of group $=NR^2$,

5


W

has the meaning of oxygen, sulfur, two hydrogen atoms or the group $=NR^8$,

Z

has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$, $(CH_2)_q-$, branched or unbranched C_{1-6} -Alkyl or is the group

10




15

or A, Z and R^1 together form the group

20

12



m, n and o

q

R_a, R_b, R_c, R_d, R_e, R_f

has the meaning of 0 – 3,

has the meaning of 1 – 6,

independently from each other have the meaning of hydrogen, C₁₋₄ alkyl or the group =NR¹⁰, and/ or R_a and/ or R_b together with R_c and or R_d or R_c together with R_e and/ or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R¹ or R²,

X

Y

p

R¹has the meaning of group =NR⁹ or =N-,has the meaning of group -(CH₂)_p,

has the meaning of integer 1-4,

has the meaning of unsubstituted or optionally substituted with one or more of halogene, C₁₋₆-alkyl, or C₁₋₆-alkyl or C₁₋₆-alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

R²

has the meaning of hydrogen or C₁₋₆-alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R₁,


R³

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or hydroxy,

R⁴, R⁵, R⁶ and R⁷

independently from each other have the meaning of hydrogen, halogen or C₁₋₆-alkoxy, C₁₋₆-alkyl or


C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R⁵ and R⁶ together form the group



- 5 R⁸, R⁹ and R¹⁰ independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts.

10 These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.


More preferentially compounds of general formula V




V,

- 15 in which
R¹ has the meaning of group


20




14



in which R⁵ is chloro, bromo or the group -OCH₃,



in which R⁷ is -CH₃ or chloro,




in which R⁸ is -CH₃, fluoro,
chloro or -CF₃

in which R⁴ is fluoro,
chloro, bromo, -CF₃,
-N=C, -CH₃, -OCF₃ or
-CH₂OH

in which R⁶ is
-CH₃ or chloro

R²

has the meaning of pyridyl or the group



and

R³

has the meaning of hydrogen or fluoro, as well as their
isomers and salts can be used as compound I or II in the inventive pharmaceutical
composition.

These compounds have the same properties as already mentioned above under
compound IV and can be used for the treatment of angiogeneous diseases.

Compositions comprise compounds of general formulars I, IV and V, alone or in
combination.

The above mentioned compounds are also claimed matter within the inventive
combinations.

A further example for ligand binding inhibitors are peptides and DNA sequences
coding for such peptides, which are used for the treatment of angiogeneous
diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59
of the sequence protocoll. It has been shown that Seq. ID Nos. 34 and 34a are of
main interest.

Claimed matter of the instant invention are therefor pharmaceutical compositions

a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

5

b) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

10

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

15

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

20

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

25

f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

30

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

The inventive compositions comprise as compound I or as compound II at least one of

10

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- 15 d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of
- 20 VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

25

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims

30 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

- 5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites formation in patients. It is also possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch, magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg.

The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

- Combined functional interference with VEGF/VEGF receptor systems and with
5 Angiopoietin/Tie receptor systems can be performed simultaneously, or in
sequential order such that the biological response to interference with one
ligand/receptor system overlaps with the biological response to interference with a
second ligand/receptor system. Alternatively, combined functional interference
with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and
10 targeting of cytotoxic agents via VEGF/VEGF receptor systems or via
Angiopoietin/Tie receptor systems can be performed simultaneously, or in
sequential order such that the biological response to functional interference with a
ligand/receptor system overlaps in time with targeting of cytotoxic agents.
- 15 The invention is also directed to a substance which functional interferes with both
VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which
are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor
systems.
- 20 VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C,
VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2
(KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1).
Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and
angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor
25 tyrosine kinases Tie1 and Tie2.

- Pharmaceutical compositions of the present invention can be used for medicinal
purposes. Such diseases are, for example, cancer, cancer metastasis,
angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of
30 the present invention can be applied orally, parenterally, or via gene therapeutic
methods.

Therefore the present invention also concerns the use of pharmaceutical
compositions for the production of a medicament for the treatment of tumors,

cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections
5 and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

5 Example 1

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10

Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with 1×10^6 transfected
15 A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60,
20 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm² (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of
- 10 expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm² to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen
- 15 succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm² to 38 days.

This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

Example 2

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in
 5 inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of
 10 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are described in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its
 15 perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000
 20 mm³ within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with

Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 3

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

10

15

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

20

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

Example 4

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is
5 superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-
10 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods
15 descibed by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor
20 growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the
- 10 coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex
- 15 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the

20 VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

Example 5

Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
 5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-
 10 B domain of fibronectin and the extracellular domain of tissue factor was expressed in E. coli as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx.
 15 200 mm³ animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

20

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducing L19 scFv-tTF (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 6

Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-
10 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of
15 treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a

10 reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm³ within 28 days.

Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

15 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

5

10

Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of a specific tyrosine kinase inhibitor and with the Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1).

The abbreviations have the following meaning:

	mock, con.	=	treatment group 1
	mock+VEGF-A	=	treatment group 2
10	sTIE2-cl13	=	treatment group 3
	sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

CLAIMS

1. Pharmaceutical compositions comprising one or several agents as compound I
which modulate the biological function of one or several of the VEGF/VEGF
5 receptor systems, and comprising one or several agents as compound II which
modulate the biological function of one or several of the Angiopoietin/Tie
receptor systems.
2. Pharmaceutical compositions comprising one or several agents as compound I
10 which are targeted to the endothelium via of one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
modulate the biological function of one or several of the Angiopoietin/Tie
receptor systems.
- 15 3. Pharmaceutical compositions comprising one or several agents as compound I
which modulates the biological function of one or several of the VEGF/VEGF
receptor systems or of one or several of the Angiopoietin/ Tie receptor systems
and comprising one or several agents as compound II which are targeted to
the endothelium.
- 20 4. Pharmaceutical compositions comprising one or several agents as compound I
which modulate the biological function of one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
are targeted to the endothelium via one or several of the Angiopoietin/Tie
25 receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I
which are targeted to the endothelium via one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
30 are targeted to the endothelium via one or several of the Angiopoietin/Tie
receptor systems.
6. Pharmaceutical compositions comprising one or several agents as compound
I which modulate the biological function of one or several of the VEGF/VEGF

receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.

- 5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 10 8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.
- 15 9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.
10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of
- 20 a) compounds which inhibit receptor tyrosine kinase activity,
b) compounds which inhibit ligand binding to receptors,
c) compounds which inhibit activation of intracellular signal pathways of the receptors,
d) compounds which inhibit or activate expression of a ligand or of a
25 receptor of the VEGF or Tie receptor system,
e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor
30 systems,
f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of

- g) compounds which inhibit receptor tyrosine kinase activity,
- h) compounds which inhibit ligand binding to receptors,
- 5 i) compounds which inhibit activation of intracellular signal pathways of the receptors,
- j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- 10 k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- 15 l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

20

13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a


14. Pharmaceutical compositions according to claims 1-11 which comprise as

25 compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.

15. Pharmaceutical compositions according to claims 1-11 which comprise as

30 compound I and/ or II at least one small molecule of general formula I

41



in which

5

r

has the meaning of 0 to 2,

n


has the meaning of 0 to 2;

 R_3 und R_4

a) each independently from each other have the meaning of lower alkyl,

10

b) together form a bridge of general partial formula II,



15


wherein the binding is via the two terminal C- atoms,
and

m

has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

20



has wherein one or two of the ring members T_1, T_2, T_3, T_4 the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

5 G has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

10 A, B, D, E and T independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

15 Q has the meaning of lower alkyl, lower alkyloxy or halogene,

R_1 and R_2 independently from each other have the meaning of H or lower alkyl,

X has the meaning of imino, oxa or thia;

20 Y has the meaning of hydrogene, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl,


25 whereas, if more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single

30

or double bonds; or an N-oxide of said compound,
 wherein one or more N-atoms carry an oxygene atom,
 or a salt thereof,

and/or a compound of general formula IV

5




in which

A has the meaning of group $=NR^2$,

10 W has the meaning of oxygen, sulfur, two hydrogen atoms
 or the group $=NR^8$,

Z has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$,
 $(CH_2)_q-$, branched or unbranched C_{1-6} -Alkyl or is the
 group


15



or A, Z and R^1 together form the group

20

44




5	m, n and o	has the meaning of 0 – 3,
	q	has the meaning of 1 – 6,
	R _a , R _b , R _c , R _d , R _e , R _f	independently from each other have the meaning of hydrogen, C ₁₋₄ alkyl or the group =NR ¹⁰ , and/ or R _a and/ or R _b together with R _c and or R _d or R _e together with R _e and/ or R _f form a bound, or up to two of the groups R _a -R _f form a bridge with each up to 3 C-atoms with R ¹ or R ² ,
10	X	has the meaning of group =NR ⁹ or =N-,
	Y	has the meaning of group -(CH ₂) _p ,
	p	has the meaning of integer 1-4,
15	R ¹	has the meaning of unsubstituted or optionally substituted with one or more of halogene, C ₁₋₆ -alkyl, or C ₁₋₆ -alkyl or C ₁₋₆ -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
20	R ²	has the meaning of hydrogen or C ₁₋₆ -alkyl, or form a bridge with up to 3 ring atoms with R _a -R _f together with Z or R ₁ ,
25	R ³	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally

R^4, R^5, R^6 and R^7

substituted with one or more of für halogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or hydroxy,


independently from each other have the meaning of hydrogen, halogene or C_{1-6} -alkoxy, C_{1-6} -alkyl or C_{1-6} -carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or R^5 and R^6 together form the group



R^8, R^9 and R^{10}

independently from each other have the meaning of hydrogen or C_{1-6} -alkyl, as well as their isomers and salts,


and/ or a compound of general formula V



V,


in which

R^1 has the meaning of group




in which R^5 is chloro, bromo or the group $-OCH_3$,

5



in which R^7 is $-CH_3$ or chloro,



in which R^8 is $-CH_3$, fluoro, chloro or $-CF_3$


in which R^4 is fluoro, chloro, bromo, $-CF_3$, $-N=C$, $-CH_3$, $-OCF_3$ or $-CH_2OH$

in which R^6 is $-CH_3$ or chloro

5

R^2

has the meaning of pyridyl or the group



10

and

R^3

has the meaning of hydrogen or fluoro, as well as their isomers and salts.

16. Pharmaceutical compositions according to claim 15 which comprise as compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

17. Pharmaceutical compositions according to claims 1-16 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II.

25

18. Pharmaceutical compositions according to claims 1-17 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium

hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

19. Pharmaceutical compositions according to claims 1-17 which comprise as
5 compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.
20. Pharmaceutical compositions according to claims 1-17 which comprise as
10 compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.
21. Pharmaceutical compositions according to claims 1-17 which comprise as
compound I L19 scFv-tTF conjugate and as compound II sTie2.
- 15 22. Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant
20 nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

25




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6

Sequence Identifier

5

<110> Schering Aktiengesellschaft

10

<120> Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use II

<130> 51867AEPm1XX00-P

15

<140>

<141>

<160> 59

20

<210> 1

<211> 1835

<212> DNA

<213> Human

25

<400> 1

30

35

40

45

50

55

60

```
ttttacagtt ttccttttct tcagagttaa ttttgaattt tcatttttgg ataaccaagc 60
agctctttta gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120
tttctttttt tttttttaa tttttttaa agtcacattc agctcgcttg ctcaaaccag 180
actcccacat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240
tatacaaaaca gccaacaaac cataatggtg ccacagggat ggagcaggga agggcatctc 300
taacgtgtcc tctagtctat cttcgctaaa cagaacccac gttacacatg ataactagag 360
agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttaa 420
aagcaaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaaggggtt 480
aagaaaacca acaacaacaa aaagcgaggg actgtctgtt gtcactgtca aaaaggcact 540
tggagttaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600
attaaaaggc ttggatgtta agagaggaca ctcagcgggt cctgaaggga gacgctgaga 660
tggaccgctg agaagcggaa cagatgaaca caaaggaatc aaatctttac aaccaaattg 720
catttaagcg acaacaaaaa aaggcaaac ccaaacgca acctaacca agcaaatct 780
aagcaaatc agacaacgaa gcagcgatgc atagctttcc tttgagagaa cgcatacctt 840
gagacgctac gtgccaacct aagttctcaa cgacagcttc acagtaggat tattgtgata 900
aaaatgactc aagcgatgca aaaagtcca tctgttccca gaatccgagg gagaactgag 960
gtgatcggtta gagcatagcg acatcacgtg cggtttctta atgtccctgg tggcggatac 1020
gccgagtcct cggaaggaca tctggacacc actttcagcc acctccttgc aggggcgaca 1080
tccgcaaaag tcatccttta ttccgagtaa taactttaat tcctttctaa catttacacg 1140
gcaaacagga atgcagtaaa cgtccacgct cgtcccacgg ctgggctgcc gttccgtttc 1200
ctccacgaac gggtagcgcg ttccatgaga aaggatattt ggcaatttta tattccacag 1260
tcagggtggg ctgcatagc tcatttaatg ttaaaccgca tcaggggcct ctccctcccg 1320
ttctgccagg ggcttttctt gtcttctcct tggcgagctc gtgggcagat cttctctggg 1380
gggggctggc tgctggctcc gagggggcat ccgcagtcgg tctggtcgtc tcctcctgca 1440
ggctgggcag ctggccacca cttctccgac tcgacccctc caacaagcat cgcagggcac 1500
tgtctcggg ggtacagacc gtggtccac attcgtacc actctgttc acgtcatcca 1560
ggtacacgag ctgctgtag gccgtgctgt ctggggctcg aggctcttcc tgctggtgct 1620
cttgacggg cggttagttc tgctgcagag acaaaagcat tccccttccc ttccgggctg 1680
atcttggttc attcatatct acgccagagt ccaaaactggc atcattactt ccgttccttc 1740
cagctctttg gagaatcaat gtatgaatgt ctaacctgac cgttgacact gccatccaag 1800
gagacgaacc acgcccgggg gtgcggaagc ggccct
```

<210> 2

<211> 581

<212> DNA

<213> Human

<400> 2

5 gttctagatt gttttattca gtaattagct ctttaagacc ctggggcctg tgctacccag 60
 acactaaca cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120
 tcaacttact tcctgtggcc cattagggaa gtggtgacct cgggagctat ttgcctgttg 180
 agtgcacaca cctggaaaca tactgctctc attttttcat ccacatcagt gagaaatgag 240
 tgccccgtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300
 10 tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360
 agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcct tgttttctct 420
 aaatgtcaag ctttgactga aaactcccg ttttccagtc actggagtgt gtgcgtatga 480
 aagaaaatct ttagcaatta gatgggagag aagggaata gtacttgaaa tgtaggcct 540
 cacctcccca tgacatcctc catgagcctc ctgatgtagt g

15 <210> 3
 <211> 516
 <212> DNA
 <213> Human

<400> 3

tagagatgtt ggttgatgac ccccgggatc tggagcagat gaatgaagag tctctggaag 60
 tcagcccaga catgtgcatc tacatcacag aggacatgct catgtcgcg aacctgaatg 120
 25 gacactcttg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180
 ttgttaagct tcgtggccag agtactgatt ctcttccaca gactatatgt cgaaaccaa 240
 agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300
 tcctgcgcat tgcaggctctg tgtcaggaca ctgctcagag ttacacctt ggatgtggcc 360
 atgaactgga tgaggaaggc ctctattgca acagttgctt ggcccagcag tgcataaca 420
 30 tccaagatgc ttttccagtc aaaagaacca gcaataactt ttctctggat ctcaactcatg 480
 atgaagtcc agagtttgtt gtgtaaagtc cgtctg

<210> 4
 <211> 1099
 <212> DNA
 35 <213> Human

<400> 4

cccacaacac agggggcctg aaacacgcca gcctctctc tgtggtcagc ttggcccagt 60
 40 cctgctcact ggtatcacag ccattgtagg tggggcatg tggggatcag ggcccctggc 120
 ccacggggag gtagaagaag acctggtccg tgtaagggtc tgagaagggt ccctgggtcg 180
 ggggtgcgtc ttggccttgc cgtgcccctc tccccggct gaggcagcga cacagcaggt 240
 gcaccaactc cagcagggtta agcaccagg agatgagtc aaccaccaac atgaagatga 300
 45 tgaagatggt cttctccgtg gggcgagaga caaagcagtc cagcaggtag gggcagggtg 360
 ctgcttggca cacaaacac ggctccatgg tccagccgta caggcgccac tggccataga 420
 ggaagcctgc ctctagcaca ctcttgacga gcacactggc gacatagggt cccatcagt 480
 ctccgaggat gcgcaggcga ccatctctg ccaccgagat cttggccatc tgacgtctta 540
 cggccgccag cggccgctcc acctgtgggt ccttggccgg cagtgcgccg agtccccct 600
 50 ccttctgccc cagccgctct tctcgccgag acaggtaaat gacatggccc aggtagacca 660
 ggggtgggtgt gctgacgaag aggaactgca gcaccagta gcgatgtgg gagatgggga 720
 aggcctggtc atagcagacg ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780
 actgctcgtc accccacact gactcgccgg ccaggccag gatgaggatg cggaagatga 840
 agagcaccgt cagccagatc ttaccacca cggtcgagt ctcctggacc tggccagca 900
 55 acttctccac gaagccccag tcaccatgg ctccggggc tccgtcggca aggagacaga 960
 gcacgtcagt gtgtcagcat ggcatccttc tcgttcgccc agcaacaagc ctgcaggag 1020
 gtctgccacg cccgttctac cgctgcctg ccggggcgcc caggtggagg tggggacgat 1080
 ggccggagtg acgcccgcg

<210> 5
 60 <211> 1015
 <212> DNA
 <213> Human

<400> 5

65 gaggataggg agcctgggggt caggagtgtg ggagacacag cgagactctg tctccaaaaa 60

	aaaaagtgtt	ttttgaaaat	gttgagggtt	aaatgatggg	aaccaacatt	ctttggattt	120
	agtggggagc	ataatagcaa	acacccccct	ggttcgcaca	tgtacaggaa	tgggacccag	180
	ttgggggcaca	gccatggact	tccccgccct	ggaatgtgtg	gtgaaaagtg	gggcccaggc	240
	ccagaccccaa	gaggagaggg	tggtcgcgag	acacccccgg	atgtcagcat	cccccgacct	300
5	gccttctggc	ggcacctccc	gggtgtgtgt	ttgagtcagc	aggcatgggg	tgagagcctg	360
	gtatatgtct	ggaacagggt	gcaggggcca	agcgttcctc	cttcagcctt	gacttggggc	420
	atgcaccccc	tctcccccaa	acacaaacaa	gcacttctcc	agtatgggtg	caggacaggt	480
	gtcccttcag	tcctctgtgt	atgacctcaa	gtcctacttg	ggccctgcag	cccagcctgt	540
	gttgtaacct	ctgctgtctc	aagaccacac	ctggaagatt	cttcttccct	ttgaaggaga	600
10	atcatcattg	ttgcttttat	acttctaaga	cattttgtac	ggcacggaca	agttaaacag	660
	aatgtgcttc	cctccctggg	gtctcacacg	ctcccacgag	aatgccacag	gggccgtgca	720
	ctgggcaggc	ttctctgtag	aaccccaggg	gcttcggccc	agaccacagc	gtcttgccct	780
	gagcctagag	cagggagtc	cgaacttctg	cattcacaga	ccacctccac	aattgttata	840
	accaaaggcc	tcctgttctg	ttatttcaat	taaatacaac	tgctattttg	ttttcactca	900
15	cttctgactt	tagcctcgtg	ctgagccgtg	tatccatgca	gtcatgttca	cgtgctagtt	960
	acgtttttct	tcttacacat	gaaaataaat	gcataagtgt	tagaagaaaa	aaaaa	
	<210> 6						
	<211> 2313						
20	<212> DNA						
	<213> Human						
	<400> 6						
25	ccagagcagg	cctgggtggt	agcaggggag	gtgcaccgga	cggcgggagc	gagcaaatgg	60
	gtctggccat	ggagcacgga	gggtcctacg	ctcggggcgg	gggcagctct	cggggctgct	120
	ggtattacct	gocetacttc	ttcctcttcg	tctccctcat	ccaattcctc	atcatcctgg	180
	ggctcgtgct	cttcatggtc	tatggcaacg	tgcacgtgag	cacagagtc	aacctgcagg	240
	ccaccgagcg	ccgagccgag	ggcctataca	gtcagctcct	agggctcacg	gcctcccagt	300
30	ccaacttgac	caaggagctc	aacttcacca	cccgcgccaa	ggatgccatc	atgcagatgt	360
	ggctgaatgc	tcgcccgcgac	ctggaccgca	tcaatgccag	cttccgccag	tgccaggggtg	420
	accgggtcat	ctacacgaac	aatcagaggt	acatggctgc	catcatcttg	agtgagaagc	480
	aatgcagaga	tcaattcaag	gacatgaaca	agagctgcga	tgcttctgtc	ttcatgctga	540
	atcagaaggt	gaagacgctg	gaggtggaga	tagccaagga	gaagaccatt	tgactaagg	600
35	ataaggaaa	cgctgctgct	aacaaacg	tgccggagga	acagctgggt	gaatgcgtga	660
	aaacccggga	gctgcagcac	caagagcgcc	actggccaag	gagcaactgc	aaaagggtgca	720
	agccctctgc	ctgcccctgg	acaaggacaa	gtttgagatg	gaccttcgta	acctgtggag	780
	ggactccatt	atcccacgca	gcctggacaa	cctgggttac	aaacctctac	atcccctggg	840
	ctcgggaatt	gctcccatcc	gcagagcctg	cgaccacatg	cccagcctca	tgagctccaa	900
40	ggtggaggag	ctggcccggg	gcctccgggc	ggatatcgaa	cgcgtggccc	gcgagaactc	960
	agacctccaa	cgccagaagc	tggaaagcca	gcagggcctg	cgggcccagc	aggaggcgaa	1020
	acagaaggtg	gagaaggagg	ctcaggcccg	ggaggccaa	ctccaaagct	aatgctccc	1080
	gcagacccag	ctagcgtggt	aggagaaggg	ggtgctgcgg	aaggaaacag	acaacctggc	1140
	caaggagctg	gaagagaaga	agaggagggc	ggagcagctc	aggatggagc	tgcccatcag	1200
45	aaactcagcc	ctggacacct	gcatacaagc	caagtcgcag	ccgatgatgc	cagtgtcaag	1260
	gcccattggg	cctgtcccca	accccagcc	catcgaccca	gctagcctgg	aggagttaa	1320
	gaggaagatc	ctggagtcct	agaggccccc	tgaggcctc	cctgtagccc	catccagtgg	1380
	ctgaggaggc	tccaggcctg	aggaccaagg	gatggcccga	ctcggcggtt	tgccgaggat	1440
	gcagggatat	gtcacagc	cccgacacaa	ccccctccg	ccgcccccaa	ccaccagg	1500
50	ccaccatcag	acaactccct	gcatacaaac	ccctagtacc	ctctcacacc	cgcaccgcg	1560
	cctcacgac	cctcaccag	agcacacggc	cgcggagatg	acgtcacgca	agcaacggc	1620
	ctgacgtcac	atatcaccgt	ggtgatggcg	tcacgtggcc	atgtagacgt	cacgaagaga	1680
	tatagcgatg	gcgtcgtgca	gatgcagcac	gtcgcacaca	gacatgggga	acttggcatg	1740
	acgtcacacc	gagatgcagc	aacgacgtca	cgggccatgt	cgacgtcaca	catattaatg	1800
55	tcacacagac	gcggcgatgg	catcacacag	acggtgatga	tgacacacac	agacacagtg	1860
	acaacacaca	ccatgacaac	gacacctata	gatatggcac	caacatcaca	tgacacgcatg	1920
	ccctttcaca	cacactttct	acccaattct	cacctagtgt	cacgttcccc	cgaccctggc	1980
	acacggggcca	aggtagccac	aggatcccat	ccccctccgc	acagccctgg	gccccagcac	2040
	ctccctcctc	ccagcttctc	ggcctccag	ccacttctct	acccccagtg	cctggaccgc	2100
60	gaggtgagaa	caggaagcca	ttcacctccg	ctccttgagc	gtgagtggtt	ccaggacccc	2160
	ctcggggccc	tgagccgggg	gtgaggggtc	cctgttgtcg	ggaggggagc	cactccttct	2220
	cccccaactc	ccagccctgc	ctgtggcccg	ttgaaatgtt	ggtggcactt	aataaatatt	2280
	agtaaatcct	taaaaaaaaa	aaaaaaaaaa	aaa			
65	<210> 7						
	<211> 389						

<212> DNA
<213> Human

<400> 7

5

gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120
tattctaaaa tcagatcctt acagatccag atttcaggaa acaaatacat aggggactaa 180
ctttccttgt tcagattagt ttttctcctt tgcacccagc tatataatat gaggaagtat 240
10 tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa tatttcggga 300
gaacctgag ctattaataa tctatgtggc tagtgcgtat atattggtct gaatttggtc 360
tccttttgtg gtgtccagtg ggtaacatc

<210> 8

15

<211> 157
<212> DNA
<213> Human

<400> 8

20

tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60
gaagcaggaa gcaagccac tcaaactgtg aatttggcat gagggatcca gtaactttct 120
cctcaatctg tgaactatat gtgagtttga tattttg

25

<210> 9
<211> 561
<212> DNA
<213> Human

30

<400> 9

aatagtcaaa acataaacia aagctaatta actggcactg ttgtcacctg agactaagtg 60
gatgttgttg gctgacatac aggtcagcc agcagagaaa gaattctgaa tcccccttgc 120
tgaactgaac tattctgtta catatggtg acaaatctgt gtgttatttc ttttctacct 180
35 acatatttta aatttatgag tatcaaccga ggacatagtc aaaccttcga tgatgaacat 240
tcctgatttt ttgcctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300
tgatgttgaa aggaaaagtg aatatgacct ttaaaaattg tattttgggt gatgatagtc 360
tcaccactat aaaactgtca attattgcct aatgttaaag atatccatca ttgtgattaa 420
ttaaaccctat aatgagtatt cttaatggag aattcttaat ggatggatta tccccctgac 480
40 ttttctttta aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540
ctgccccaat ttctaggaaa a

<210> 10

45

<211> 1508
<212> DNA
<213> Human

<400> 10

50 cacaaacacg agagactcca cggctctgcct gagcaccgcc agcctcctag gctccagcac 60
tcgcaggtcc attcttctgc acgagcctct ctgtccagat ccataagcac ggctcagctca 120
gggtcgcgga gcagtacgag gacaagtacc agcagcagct cctctgaaca gagactgcta 180
ggatcatcct tctctccgg gctgttgcct gatggcataa tccgggtgca acccaaatct 240
gagctcaagc caggtgagct taagccactg agcaaggaag atttgggcct gcacgcctac 300
55 aggtgtgagg actgtggcaa gtgcaaatgt aaggagtga cctaccceaag gcctctgcca 360
tcagactgga tctgcgacaa gcagtgcctt tgctcggccc agaactgatg tgactatggg 420
acttgtgtat gctgtgtgaa aggtctcttc tatcactgtt ctaatgatga tgaggacaac 480
tgtgctgaca acccatgttc ttgcagccag tctcactgtt gtacacgatg gtcagccatg 540
gggtgctatgt cctcttttt gccttgttta tgggtgttacc ttccagccaa ggggtgcctt 600
60 aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660
aacacagttt gctgcaaaagt tcccactgtc ccccttagga actttgaaaa accaactatg 720
catcattaat caggaatatt acagtaatga ggattttttc tttctttttt taatacacat 780
atgcaaccaa ctaaacagtt ataacttttg cactgttaat agaaagtgtg gatagtcttt 840
gctgttttgc gtgaaatgct ttttgtccat gtgccgtttt aactgatatg cttgttagaa 900
65 ctcagctaatt ggagctcaaa gtatgagata cagaacttgg tgaccatgt attgcataag 960
ctaaagcaac acagacactc ctaggcaaaag tttttgtttg tgaatagtac ttgcaaaact 1020

5 tgtaaattag cagatgactt ttttccattg ttttctccag agagaatgtg ctatatTTTT 1080
 gtatatataa taatatTTTgc aactgtgaaa aacaagtggg gccatactac atggcacaga 1140
 cacaaaatat tatactaata tgtgtgacat tcggaagaat gtgaatcaat cagtattgtt 1200
 ttagattgta ttttgcctta cagaaagcct ttattgtaag actctgattt ccctttggac 1260
 10 ttcattgtata ttgtacagtt acagtaaaat tcaaccttta ttttctaatt ttttcaacat 1320
 attgtttagt gtaaagaata tttatttgaa gttttattat tttataaaaa agaattttta 1380
 ttttaagagg catcttataa attttgcccc ttttatgagg atgtgatagt tgctgcaaat 1440
 gaggggttac agatgcataat gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500
 aaaaaaaa
 <210> 11
 <211> 389
 <212> DNA
 <213> Human
 15 <400> 11
 gggcaggtga tcagggcaca catttcccggt ccattgagac agtagcattc ccggcaccca 60
 20 tcgtgccagc tctcctcatt tttatgatga tgaccatcca cgggtgagaca agtgcccagc 120
 aggatgggtg gccagctga agcacaggcc gctctgcatg tgcagataag acagccgtga 180
 ctgtcctgct ggaaacccaa ggggcagatc ttactgcatg agagctctgg acattttcta 240
 cagcgacaga tgtcacagcc gtgcttattc ttcagcaatc caagtggaca atacttgtca 300
 cagattatgg gtctgcactt cttgggcctt gggcggcact cacagatctc acagttttgg 360
 25 acctcggccg cgaccacgct gggatccga
 <210> 12
 <211> 981
 <212> DNA
 <213> Human
 30 <400> 12
 tttttttttt ttggattgca aaaatttatt aaaattggag acactgtttt aatctttctt 60
 35 tggcatgaga ctccatcagg cagtctacaa agaccactgg gaggtgagg atcacttgag 120
 ccagaaagtt tgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180
 aagacccttt caagcagtaa gctgcatgct tgcttgttgt ggtcattaaa aaccctagtt 240
 taggataaca acatattaat cagggcaaaa tacaaatgtg tgatgcttgt tagtagagta 300
 acctcagaat caaaatggaa cggttttaca gtgatcatat tatatttcat ttggcagaat 360
 40 cattacatca ttggttacac tgaaaatcat cacatgtacc aaaagctgac tcacctagtt 420
 taggataaca ggtctgcctg tttgaagatg aaaaaataa cccatttaaa atttgcccta 480
 ctcaatttcc ttctcagtca cattttaact tttaaacagc taatcactcc catctacaga 540
 ttaaggtgta tatgccacca aaaccttttg ccaccttaaa aatttccttc aaagttaaaa 600
 ctaatgcctg catttcttca atcatgaatt ctgagtcctt tgcttcttta aaacttgctc 660
 45 cacacagtgt agtcaagccg actctccata cccaagcaag tcatccatgg ataaaaacgt 720
 taccaggagc agaaccatta agctgggtcca ggcaagttgg actccaccat ttcaacttcc 780
 agctttctgt ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggacttc 840
 agtagctatt ctcatccttc cttggggaca caactgtcca taaggtgcta tccagagcca 900
 cactgcatct gcaccagca ccatacctca caggagtcca ctcccacgag ccgcctgtat 960
 50 ataagagttc ttttgatgac g
 <210> 13
 <211> 401
 <212> DNA
 <213> Human
 55 <400> 13
 ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60
 60 aagagagccc ggccgcagag catgtgactg ctgggacctc tgggataggc aacactgccc 120
 tctctcccc agagcgaccc cccgggcagg tcggggccca aggaatgacc cagcaactgc 180
 tccctaccca gcacactctc ttactgcca cctgcaatta tgctgtgaag atgactgggt 240
 gtggatcatc cgattcagag aaatcaagat ctatgacat tttaggcaaa gagagaaact 300
 tggagaattg ctgaggacta ctgaaccttg ttttgctttt ttaaaaaata ctaaatcctc 360
 65 acttcagcat atttagttgt cattaaaatt aagctgatat t
 <210> 14

<211> 1002
 <212> DNA
 <213> Human

5 <400> 14

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
 acagttgtgg agaacagggt gagtagagca acaacaacaa aagcttatgc agtcaccttc 120
 10 tttgaaaatg ttaaatacaaa gtcctattct ctttgtccag ctgggttag cttaggtag 180
 ccaattactt ctcttaaggt ccatggcatt cgccaggatt ctataaaagc caagttaact 240
 gaagtaaata tctggggccc atcgacccc cactaagtac tttgtcacca tgtgtatct 300
 taaaagtcatt ttttctactgt ttgactcaga atttgggact tcagagtcaa acttcattgc 360
 ttactccaaa cccagtttaa ttcccactt ttttaagtag gcttagcttt gagtgatttt 420
 tggctataac cgaatgtaa atccacctt aaacaacaaa gtttgacaag actgaaatgt 480
 15 tactgaaaa aatggtgcca tatgtccaa agacatttcc ccaagataac tgccaaagag 540
 tttttgagga ggacaatgat catttattat gtagggagcct tgatatctct gcaaaataga 600
 attaatacag ctcaaatgga gtagtaacca agcttttctg cccaggaagt aacaacatc 660
 actacgaaca tgagagtaca agaggaaact ttcataatgc attttttcat tcatacattc 720
 attcaataaa cattagccaa gctaattgtc caagccactg tgccaggtat taacaatata 780
 20 acaacaataa aagacacagt ccttctcttc aaggtgttca gtctagtagg gaagatgatt 840
 attcattaaa atttttggg catcagaatc atgaggagct tgtcaaaaat gtaaatctct 900
 gcctatgttc tcagatattc tggttagggtc aggagtggga acccaaatc aattctttta 960
 acaaacacta aaggtgatcc taacacaggc ggtgtgagga cc

25 <210> 15
 <211> 280
 <212> DNA
 <213> Human

30 <400> 15

cgaggtgggc caccctgtgc tggctctgaga tttttaaatg aggattacat taccctattt 60
 ataattattcc tattctaatc tattgtattc ttacaattaa atgtatcaaa taattcttaa 120
 aaactgtatt agaaacaaac tgccataatc cttataagac taaaaaaatc accaagatga 180
 35 aactgtatta tgactctcaa tatttaaaaa ttttaaaaaa tgttagtggt tgttaagcac 240
 caatcttaac tatttcacct gcccgggcgg ccgctcgagg

<210> 16
 <211> 2041
 40 <212> DNA
 <213> Human

<400> 16

45 cccccgcgag aactcccccc tggaaatagga tttttaaaac ccttgacaat tagaaatcct 60
 atagagggtta gcatttttta ggtaaaaata tgggtgcccc tacagggatc atgcaacttc 120
 cttaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtacttgaa 180
 atacagacac agtcatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240
 aattttgtta ttgccttctt tagagacttt ataactctca gttgattttc aaggacttga 300
 50 atttaataat ggggtaatta cacaagacgt aaaggatttt ttaaaaacaa gtattttttt 360
 ttacctctag catcaattct tttataaaga atgctaaata aattacattt tttgttcagt 420
 aaaactgaag atagaccatt taaatgcttc taccaaattt aacgcagctt aattagggac 480
 cagggtacata ttttcttctg aacattttttg tccaagcatg tctaaccata aaagcaaatg 540
 gaatttttaag aggtagattt tttttccatg atgcattttg ttaataaatg tgtcaagaaa 600
 55 ataaaaacaa gcactgagtg tgttctcttg aagtataagg gtctaataaa aaataaaaaga 660
 tagatatttg ttatagtctg acattttaac agtcatagta tttagcgttt cgtgaccagt 720
 gcatttttga ctctctcagg atcaaaaatac gaggctgcca actgtattaa atctctctcc 780
 accccctcca ccagttggtc cacagcttcc tgggtgggtcg ttgtcatcaa atccattggg 840
 ccgaaatgaa catgaagcag atgcagcttg gagggcccgg gctcgagcat tcaactcttg 900
 60 ttctgtgtaa tatagtttat tgtcttttgt tatagcatcc ataagttctt tctgtagagg 960
 tgggtctcca tttatccaga gtccactggg tgggttatta ccacttaaac cattagtact 1020
 atgctgtttt ttatacaaaa gcacataagc tgtgtccttt ggaaaacctgc tcgtaatttt 1080
 ctggactgac tgaaatgaag taaatgtcac tctactgtca ttaataaaaa acccattctt 1140
 ttgacatttc cttattttcc aaatcctgtt caaaaactgc actgggacta tctctcccta 1200
 65 gtaaatgact ctgggaggat gctaattgcca gagcctcaga ctggtggtac atctgatatg 1260
 aagagtctgt acttgtgata tttctggcat aagaatagta atgccactt tcagaggata 1320

	taccagagtg	aaccacaacg	gaacttaata	gatagggcac	caattttgtg	caggaagctt	1380
	catcagtgccc	tgaaggcttt	aatttttttag	caagggtctc	actaagatca	gtgaagtcaa	1440
	catctacaga	ccaactttct	gacaatgaag	agaaagaagt	aattcttcta	actggcaact	1500
	ccaaaaccag	tggccagtg	tacattgtct	aaaattttcc	ttctcacatg	atacttctga	1560
5	tcatatgaaa	atctcaggag	agtaagaata	aggtattcag	gttcctccgt	gatttgcata	1620
	gttttctcag	cattttgcag	agaggcacag	ttttcacaat	aattattggt	atcaccagta	1680
	agaatctctg	gagcccaaaa	aataatttag	taagtcagtt	actgaagggtg	tggtttcacc	1740
	tcccggtttc	tgagggtacat	ctttattaac	aagaatcttg	ttagattcgt	tagggacaga	1800
	agtgttttca	gaacagtaaa	actcattagg	aggactgcct	atgggttttt	cattcacaag	1860
10	tgagtcacag	atgaaggcag	ctgttggttg	attataaact	actggctctt	ctgaaggacc	1920
	gggtacagac	gcttgcatga	gaccaccatc	ttgtatactg	gggtgatgatg	ctggatcttg	1980
	gacagacatg	ttttccaaag	aagaggaagc	acaaaacgca	agcgaaagat	ctgtaaaggc	2040
	t						
15	<210>	17					
	<211>	235					
	<212>	DNA					
	<213>	Human					
20	<400>	17					
	cgccccgggc	aggtgtcagg	ggttccaaac	cagcctgggg	aaacacagcg	tagacccctc	60
	acctctacaa	ataaaaaatt	aaaaaattag	ccaggtgtgg	cagcgaaaca	ctgtagtctc	120
	agatactcag	gagactgagc	tggaaaggat	cacttgagcc	caagaagttc	aaggttacag	180
25	tgggccacga	tcatgtcatt	acactccagc	ttgggtgaca	aatgagact	gtcta	
	<210>	18					
	<211>	2732					
	<212>	DNA					
30	<213>	Human					
	<400>	18					
	gtgtggagtt	tcagctgcta	ttgactataa	gagctatgga	acagaaaaag	cttgctggct	60
35	tcatgttgat	aactacttta	tatggagctt	cattggacct	gttaccttca	ttattctgct	120
	aaatattatc	ttcttggtga	tcacattgtg	caaaatgggtg	aagcattcaa	acactttgaa	180
	accagattct	agcagggttg	aaaacattaa	gtcttggttg	cttggcgctt	tcgctcttct	240
	gtgtcttctt	ggcctcacct	ggtccttttg	gttgcttttt	attaatgagg	agactattgt	300
	gatggcatat	ctcttcacta	tatttaatgc	tttccaggga	gtgttcattt	tcactcttca	360
40	ctgtgctctc	caaaagaaaag	tacgaaaaga	atatggcaag	tgcttcagac	actcatactg	420
	ctgtggaggc	ctcccaactg	agagtcccca	cagttcagtg	aaggcatcaa	ccaccagaac	480
	cagtgtctcg	tattcctctg	gcacacagag	tcgtataaga	agaatgtgga	atgatactgt	540
	gagaaaaaca	tcagaatcct	cttttatctc	aggtgacatc	aatagcactt	caacacttaa	600
	tcaaggtggc	ataaaatctta	atatattatt	acaggactga	catcacatgg	tctgagagcc	660
45	catcttcaag	atttatatca	tttagaggac	attcactgaa	caatgccagg	gatacaagtg	720
	ccatggatac	tctaccgcta	aatggtaatt	ttaacaacag	ctactcgctg	cacaagggtg	780
	actataatga	cagcgtgcaa	gttggtgact	gtggactaag	tctgaatgat	actgcttttg	840
	agaaaatgat	catttcagaa	ttagtgcaca	acaacttacg	gggcagcagc	aagactcaca	900
	acctcgagct	cacgctacca	gtcaaacctg	tgattggagg	tagcagcagt	gaagatgatg	960
50	ctattgtggc	agatgcttca	tctttaatgc	acagcgacaa	cccagggtcg	gagctccatc	1020
	acaaagaact	cgaggcacca	cttattcctc	agcggactca	ctcccttctg	taccaacccc	1080
	agaagaaagt	gaagtccgag	ggaactgaca	gctatgtctc	ccaactgaca	gcagaggctg	1140
	aagatcacct	acagtccccc	aacagagact	ctctttatac	aagcatgccc	aatcttagag	1200
	actctcccta	tccggagagc	agccctgaca	tggagaaga	cctctctccc	tccaggagga	1260
55	gtgagaatga	ggacatttac	tataaaagca	tgccaaatct	tggagctggc	catcagcttc	1320
	agatgtgcta	ccagatcagc	aggggcaata	gtgatggtta	tataatcccc	attaacaaag	1380
	aagggtgtat	tccagaagga	gatgttagag	aaggacaaat	gcagctgggt	acaagtcttt	1440
	aatcatacag	ctaaggaatt	ccaagggcca	catgcgagta	ttataaaata	aagacaccat	1500
	tggcctgacg	cagctccctc	aaactctgct	tgaagagatg	actcttgacc	tgtggttctc	1560
60	tgggtgtaaaa	aagatgactg	aaccttgtag	ttctgtgaat	ttttataaaa	catacaaaaa	1620
	ctttgtatat	acacagagta	tactaaagtg	aattatttgt	tacaaagaaa	agagatgcca	1680
	gccagggtatt	tttaagattct	gctgtgtgtt	agagaaattg	tgaacaagc	aaaacaaaaa	1740
	tttccagcca	ttttactgca	gcagtctgtg	aactaaattt	gtaaatatgg	ctgcaccatt	1800
	tttgtaggcc	tgcattgtat	tatatacaag	acgtaggctt	taaaatcctg	tgggacaaat	1860
65	ttactgtacc	ttactattcc	tgacaagact	tggaaaagca	ggagagatat	tctgcatcag	1920
	tttgtagttc	actgcacaa	ttttacatta	aggcaagat	tgaacacatg	cttaaccact	1980

	agcaatcaag	ccacaggcct	tatttcatat	gtttcctcaa	ctgtacaatg	aactattctc	2040
	atgaaaaatg	gctaaagaaa	ttatatatttg	ttctattgct	agggtaaaat	aaatacattt	2100
	gtgtccaact	gaaatataat	tgtcattaaa	ataattttaa	agagtgaaga	aaatattgtg	2160
5	aaaagctctt	ggttgcacat	gttatgaaat	gttttttctt	acactttgtc	atggtaagtt	2220
	ctactcattt	tcacttcttt	tcacttgtat	acagtgttct	gctttgacaa	agttagtctt	2280
	tattacttac	atttaaattt	cttattgcca	aaagaacgtg	ttttatgggg	agaaacaaac	2340
	tctttgaagc	cagttatgtc	atgccttgca	caaaagtgat	gaaatctaga	aaagattgtg	2400
	tgtcaccctt	gtttattctt	gaacagaggg	caaagagggc	actgggcact	tctcacaac	2460
10	tttctagtga	acaaaagggtg	cctatttctt	tttaaaaaaa	taaaataaaa	cataaatatt	2520
	actcttccat	attccttctg	cctatatatta	gtaatttaatt	tattttatga	taaagttcta	2580
	atgaaatgta	aattgtttca	gcaaaattct	gctttttttt	catccctttg	tgtaaacctg	2640
	ttaataatga	gccccact	aatatccagt	gtaaagttta	acacggtttg	acagtaaata	2700
	aatgtgaatt	ttttcaagtt	aaaaaaaaaa	aa			
15	<210>	19					
	<211>	276					
	<212>	DNA					
	<213>	Human					
20	<400>	19					
	ctccctaaat	gatttttaaaa	taaattggat	aaacatatga	tataaagtgg	gtacttttaga	60
	aaccgccttt	gcatattttt	tatgtacaaa	tctttgtata	caattccgat	gttccttata	120
25	tattccctat	atagcaaacc	aaaaccagga	cctcccaact	gcatgcctca	agtccctgtg	180
	gagcactctg	gcaactggat	ggccctactt	gctttctgac	aaaatagctg	gaaaggagga	240
	gggaccaatt	aaatacctcg	gccgcgacca	cgctgg			
	<210>	20					
	<211>	2361					
30	<212>	DNA					
	<213>	Human					
	<400>	20					
35	attgtaccag	ccttgatgaa	cgtgggccc	gcttcgcttt	tgagggccat	aagctcattg	60
	cccactgggt	tagaggctac	cttatcattg	tctcccgtga	ccggaagggt	tctcccaagt	120
	cagagtttac	cagcagggat	tcacagagct	ccgacaagca	gattctaaac	atctatgacc	180
	tgtgcaacaa	gttcatagcc	tatagcaccg	tctttgagga	tgtagtggat	gtgcttgctg	240
40	agtggggctc	cctgtacgtg	ctgacgcggg	atgggcgggt	ccacgcactg	caggagaagg	300
	acacacagac	caaactggag	atgctgttta	agaagaacct	atttgagatg	gcgattaacc	360
	ttgccaaagag	ccagcatctg	gacagtgatg	ggctggccca	gattttcatg	cagtatggag	420
	accatctcta	cagcaagggc	aaccacgatg	gggctgtcca	gcaatatatc	cgaaccattg	480
	gaaagtggga	gccatcctac	gtgatccgca	agtttctgga	tgcccagcgc	attcacaacc	540
45	tgactgccta	cctgcagacc	ctgcaccgac	aatccctggc	caatgccgac	cataccaccc	600
	tgctcctcaa	ctgctatacc	aagctcaagg	acagctcgaa	gctggaggag	ttcatcaaga	660
	aaaagagtga	gagtgaagtc	cactttgatg	tggagacagc	catcaaggtc	ctccggcagg	720
	ctggctacta	ctcccatgcc	ctgtatctgg	cggagaacca	tgacatcat	gagtggtagc	780
	tgaagatcca	gctagaagac	attaagaatt	atcaggaagc	ccttcgatac	atcggcaagc	840
	tgcttttga	gcaggcagag	agcaacatga	agcgtacagg	caagatcctc	atgcaccaca	900
50	taccagagca	gacaactcag	ttgctgaagg	gactttgtac	tgattatcgg	cccagcctcg	960
	aaggccgcag	cgataggggag	gccccaggct	gcagggccaa	ctctgaggag	ttcatcccca	1020
	tctttgcgca	taaccgcgca	gagctgaaag	ccttcctaga	gcacatgagt	gaagtgcagc	1080
	cagactcacc	ccaggggatc	tacgacacac	tccttgagct	gcgactgcag	aactggggccc	1140
55	acgagaagga	tccacaggtc	aaagagaagc	ttcacgcaga	ggccatttcc	ctgctgaaga	1200
	gtggctcgctt	ctgcgacgtc	tttgacaagg	ccctggctct	gtgccagatg	cacgacttcc	1260
	aggatgggtg	cctttacctt	tatgagcagg	ggaagctggt	ccagcagatc	atgcactacc	1320
	acatgcagca	cgagcagtag	cggcaggcca	tcagcgtgtg	tgagcgccat	ggggagcagg	1380
	accctcctt	gtgggagcag	gccctcagct	acttcgctcg	caaggaggag	gactgcaagg	1440
	agtatgtggc	agctgtcctc	aagcatatcg	agaacaagaa	cctcatgccca	cctcttctag	1500
60	tggtgcagac	cctggcccac	aactccacag	ccacactctc	cgatcatcag	gactacctgg	1560
	tccaaaaact	acagaaacag	agccagcaga	ttgcacagga	tgagctgcgg	gtgcggcggt	1620
	accgagagga	gaccaccctg	atccgccagg	agtcacaaga	gctcaaggcc	agtcctaaga	1680
	ttttccaaaa	gaccaagtgc	agcatctgta	acagtgccct	ggagttgccc	tcagtcact	1740
	tctgtgtggg	ccactccttc	caccaacact	gctttgagag	ttactcgga	agtgatgctg	1800
65	actgcccac	ctgcctccct	gaaaaccgga	aggtcatgga	tatgatccgg	gccagggaac	1860
	agaaacgaga	tctccatgat	caattccagc	atcagctcaa	gtgctccaat	gacagctttt	1920

	ctgtgattgc	tgactacttt	ggcagagggtg	ttttcaacaa	attgactctg	ctgaccgacc	1980
	ctccccagc	cagactgacc	tccagcctgg	aggctgggct	gcaacgcgac	ctactcatgc	2040
	actccaggag	gggcacttaa	gcagcctgga	ggaagatgtg	ggcaacagt	gaggaccaag	2100
	agaacagaca	caatgggacc	tgggcgggcg	ttacacagaa	ggctggctga	catgcccagg	2160
5	gctccactct	catctaattg	cacagccctc	acaagactaa	agcggaactt	tttcttttcc	2220
	ctggccttcc	ttaattttta	gtcaagcttg	gcaatccctt	cctctttaac	taggcagggtg	2280
	ttagaatcat	ttccagatta	atggggggga	aggggaacct	caggcaaacc	tcctgaagtt	2340
	ttgaaaaaaa	aagctggttt	c				
10	<210> 21						
	<211> 179						
	<212> DNA						
	<213> Human						
15	<400> 21						
	agggtgtaga	tgctcttgaa	aaagaaactg	catctaagct	gtcagaaatg	gattctttta	60
	acaatcaact	aaaggaactg	agagaaacct	acaacacaca	gcagttagcc	cttgaacagc	120
	tttataagat	caacgtgaca	agttgaagga	aattgaaagg	aaaaaattag	aactaatgc	
20	<210> 22						
	<211> 905						
	<212> DNA						
	<213> Human						
25	<400> 22						
	tttttttttt	ttctttaacc	gtgtggtctt	tatttcagtg	ccagtgttac	agatacaaca	60
	caaatgttcc	agtttagaag	aattcaaacy	gaatgccaag	gtccaagcca	ggctcaagaa	120
30	ataaaaaagg	aggtttgag	taatagataa	gatgactcca	atactcactc	ttcctaagg	180
	caaaggtact	tttgatacag	agtctgatct	ttgaaactgg	tgaactcctc	ttccacccat	240
	taccatagtt	caaacaggca	agttatgggc	ttaggagcac	tttaaaattt	gtgggtggga	300
	tagggtcatt	aataactatg	aatatatctt	ttagaagggtg	accattttgc	actttaaagg	360
	gaatcaattt	tgaaaatcat	ggagactatt	catgactaca	gctaaagaat	ggcgagaaa	420
35	gggagctgga	agagccttgg	aagtttctat	tacaaataga	gcaccatata	cttcatgcca	480
	aatctcaaca	aaagctcttt	ttaactccat	ctgtccagtg	tttacaataa	aactcgcaag	540
	gtctgaccag	ttcttggtta	caaacataca	tgtgtgtgtc	tgtgtgtata	cagcaatgca	600
	cagaaaaggc	taccaggagc	ctaatagcctc	tttcaaacat	tgggggaacc	agtagaaaaa	660
	ggcagggtc	cctaattgtc	attattacat	ttccattccg	aatgccagat	gttaaaagt	720
40	cctgaagatg	gtaaccagc	tagtgaggaa	taaatacccc	accttgccca	gtccacagag	780
	aaacaacagt	agaaagaagg	ggcaactctt	tgctgcagag	acaaagtgg	tgttttttcg	840
	ccatggattg	cagtcctctc	ctccagacca	gctgcttatt	tcctcagggg	cccagggaat	900
	gttga						
45	<210> 23						
	<211> 2134						
	<212> DNA						
	<213> Human						
50	<400> 23						
	ggctctctct	ttcctttttt	tttttccaaa	agtgttcttt	tatttctagt	aacatatatt	60
	gtataaaatac	tctattttat	atgcacttcc	acaaaagcga	tataatttaa	aagttttttt	120
	cattagaaat	aaatgtataa	aaataaata	gttattatag	gcattttatta	ctaactatag	180
55	tccttcttgg	aaggaacacc	caaaccaata	cttataaagt	acatgtaat	tatagtaaca	240
	tattttacta	tatacatatg	gaaaaaatca	tattctcaca	gaagagctga	acagacattc	300
	accaggatac	gactgttgga	ccagctgctg	gagatggacc	tgctaccctc	cagcagcctc	360
	cccaccacaa	gacaagtgat	ctcaatgtcc	ccaaacctgt	gggacctgt	tctacacacc	420
	tcatttttgt	tccggcggtt	catcctcctt	gtgtgattgt	actgattttc	atgagacaca	480
60	agttacttct	ttacatccat	attcccaaag	caggggttaca	tggtaggaaa	gaaagggaagt	540
	tggaggtact	aagctcattg	tgtctcctct	agcttttacc	agcatctaata	gcttcactgc	600
	tttttttcca	ttgtagactt	taatgcactt	gaataaatac	atggagtgtg	tttttctca	660
	aaatgaatta	cacaaataaa	gactgagatg	gtccaaaaaa	ggaaagagga	agccatttgc	720
	gttattttcac	gttgctgagc	ctttctctca	tgttgaacaa	tctgaagttt	taattctcgg	780
65	tagaaataat	gtataaacat	tctctgaaac	catagcagcc	ataaacagt	ctggtcaaag	840
	atcctatttg	tactcctttc	tccccccatt	gttagtgagg	taaagtaaaa	caggtcttag	900

	taaaatctca	cttttctcct	acttttcatt	tcccaacccc	catgatacta	agtatttgat	960
	aagtaccagg	aaacaggggt	tgtaatagtt	ctaacttttt	ttgacaattg	ctttgttttt	1020
	tctaaacttg	taatagatgt	aacaaaagaa	ataataataa	taatgcccgg	ggctttatta	1080
	tgctatatca	ctgctcagag	gttaataatc	ctcactaact	atcctatcaa	atttgcaact	1140
5	ggcagtttac	tctgatgatt	caactccttt	tctatctacc	cccataatcc	caccttactg	1200
	atacacctca	ctggttactg	gcaagatacg	ctggatccct	ccagccttct	tgctttccct	1260
	gcaccagccc	ttcctcactt	tgctttgccc	tcaaagctaa	caccacttaa	accacttaac	1320
	tgcatctctg	cattgtgcaa	aagtctatga	aatgtttagg	tttctttaaa	ggatcacagc	1380
	tctcatgaga	taacacccct	ccatcatggg	acagacactt	caagcttctt	tttttgtaac	1440
10	ccttcccaca	ggtcttagaa	catgatgacc	actccccag	ctgccactgg	gggcagggat	1500
	ggtctgcaca	aggtctgggt	ctggctggct	tcacttcctt	tgcacactcg	gaagcaggct	1560
	gtccattaat	gtctcggcat	tctaccagtc	ttctctgcca	acccaattca	catgacttag	1620
	aacattcgcc	ccactcttca	atgacccatg	ctgaaaaagt	ggggatagca	ttgaaagatt	1680
	ccttcttctt	ctttacgaag	taggtgtatt	taattttagg	tcgaagggca	ttgcccacag	1740
15	taagaacctg	gatggctcaag	ggctctttga	gagggctaaa	gctgcgaatt	ctttccaatg	1800
	ccgcagagga	gccgctgtac	ctcaagacaa	cacctttgta	cataatgtct	tgctctaagg	1860
	tggaacaaagt	gtagtcacca	ttaagaatat	atgtgccatc	agcagctttg	atggcaagaa	1920
	agctgccatt	gttcctggat	cccctctggt	tccgctgttt	cacttcgatg	ttggtggctc	1980
	cagttggaat	tgtgatgata	tcatgatatc	caggttttgc	actagtaact	gatcctgata	2040
20	tttttttaca	agtagatcca	tttccccgcg	aaacaccaca	tttatcaaac	ttctttttgg	2100
	agtcctatgat	gcgatcacaa	ccagctttta	caca			
	<210>	24					
	<211>	1626					
25	<212>	DNA					
	<213>	Human					
	<400>	24					
30	ggacaatttc	tagaatctat	agtagtatca	ggatatattt	tgcttttaaaa	tatattttgg	60
	ttattttgaa	tacagacatt	ggctccaaat	tttcatcttt	gcacaatagt	atgacttttc	120
	actagaactt	ctcaacattt	gggaactttg	caaatatgag	catcatatgt	gttaaggctg	180
	tatcatttta	tgctatgaga	tacattgttt	tctccctatg	ccaaacaggt	gaacaaacgt	240
	agttgttttt	tactgatact	aaatgttggc	tacctgtgat	tttatagtat	gcacatgtca	300
35	gaaaaaggca	agacaaatgg	cctcttgtag	tgaatacttc	ggcaaaactta	ttgggtcttc	360
	attttctgac	agacaggatt	tgaactcaata	tttgtagagc	ttgcgtagaa	tggtattacat	420
	ggtagtgatg	cactgggtaga	aatgtgtttt	agttattgac	tcagaattca	tctcaggatg	480
	aatcttttat	gtctttttat	tgtaagcata	tctgaattta	ctttataaag	atggtttttag	540
	aaagctttgt	ctaaaaattt	ggcctaggaa	tggttaacttc	attttcagtt	gccaaggggt	600
40	agaaaaataa	tatgtgtggt	gttatgttta	tgtaaacata	ttattaggta	ctatctatga	660
	atgtatttaa	atatttttca	tattctgtga	caagcattta	taatttgcaa	caagtggagt	720
	ccatttagcc	cagtgggaaa	gtcttggaac	tcagggttacc	cttgaaggat	atgctggcag	780
	ccatctcttt	gatctgtgct	taaactgtaa	tttatagacc	agctaaatcc	ctaacttgga	840
	tctggaatgc	attagttatg	ccttgtagca	ttcccagaat	ttcaggggca	tcgtgggttt	900
45	ggtctagtga	ttgaaaacac	aagaacagag	agatccagct	gaaaaagagt	gatcctcaat	960
	atcctaacta	actggctctc	aactcaagca	gagtttcttc	actctggcac	tgtgatcatg	1020
	aaacttagta	gaggggattg	tgtgtatttt	atacaaat	aatacaatgt	cttacattga	1080
	taaaattctt	aaagagcaaa	actgcatttt	atttctgcat	ccacattcca	atcatattag	1140
	aactaagata	tttatctatg	aagatataaa	tggtgcagag	agactttcat	ctgtggattg	1200
50	cgttgtttct	tagggttcct	agcactgatg	cctgcacaag	catgtgatat	gtgaaataaa	1260
	atggattctt	ctatagctaa	atgagttccc	tctggggaga	gttctgtgtac	tgcaatcaca	1320
	atgccagatg	gtgtttatgg	gctattttgtg	taagtaagtg	gtaagatgct	atgaagtaag	1380
	tgtgtttgtt	ttcatcttat	ggaaactctt	gatgcattgtg	cttttgtagt	gaataaat	1440
	tggtgcaata	tgatgtcatt	caactttgca	ttgaattgaa	ttttggttgt	atttatatgt	1500
55	attatactcg	tcacgcttct	agttgcttca	accattttat	aaccattttt	gtacatat	1560
	tacttgaaaa	tatttttaaat	ggaaatttaa	ataaacattt	gatagtttac	ataataaaaa	1620
	aaaaaa						
	<210>	25					
	<211>	1420					
	<212>	DNA					
	<213>	Human					
	<400>	25					
60	gttcagcatt	gtttctgctt	ctgaaatctg	tatagtacac	tggtttgtaa	tcattatgtc	60

5 ggtgaactca gtgcattggg ccaatgggtc gacacaggct ctgccagcca caaccatcct 60
 gctgcttctg acgggtttggc tgctgggtgg ctttcccttc actgtcattg gaggcattct 120
 tgggaagaac aacgccagcc cctttgatgc accctgtcgc accaagaaca tcgcccggga 180
 gattccaccc cagccctggg acaagtctac tgtcatccac atgactgttg gaggcttcct 240
 gcctttcagt gccatctctg tggagctgta ctacatcttt gccacagtat ggggtcggga 300
 gcagtacact ttgtacggca tcctcttctt tgtcttcgcc atcctgctga gtgtgggggc 360
 ttgcatctcc attgcaactca cctacttcca gttgtctggg gaggattacc gctgggtggg 420
 10 gcgatctgtg ctgagtgttg gctccaccgg cctcttcac ttcctctact cagtttttcta 480
 ttatgcccgg cgctccaaca tgtctggggc agtacagaca gtagagtctt tcggctactc 540
 cttactcact ggttatgtct tcttctcat gctgggcacc atctcctttt tttcttcctt 600
 aaagttcatc cgggtatatct atgttaacct caagatggac tgagtctctg atggcagaac 660
 tattgtctgt ctctcccttt ctctatgcc tgttgaactc tcctaccagc ttctctctg 720
 attgactgaa ttgtgtgatg gcattgttgc ctccctttt tccctttggg cattccttcc 780
 15 ccagagaggc cctggaaatt ataaatctct atcacataag gattatata ttgaactttt 840
 taagttgcct ttagtttttg tctgtatttt tctttttaca attacaaaaa taaaatttat 900
 taagaaaaag aaaaaaaaaa aaaaaaaaaa

<210> 29
 20 <211> 1775
 <212> DNA
 <213> Human

<400> 29

25 gaacgtgatg ggaacttttg gaggatgtct gagaaaatgt ccgaagggat tttggccaac 60
 accagaaaac gccaatgtcc taggaattcc ctcccaaat gcttcccaaa aaattactca 120
 ttgacaattc aaattgcact tggttgccgg cagcccgggc ggccttcagt ccgtgtgggg 180
 cgcccgcgtg gccttctcct cgtaggactc cccaaactcg ttactctgc gtttatccac 240
 30 aggataaaag caccgctggt acaggtagac cagaaacacc acgtcgtccc ggaagcaggc 300
 cagccggtga gacgtgggca tgggtgatgat gaaggcaaa acgtcatcaa tgaagggtgt 360
 gaaagccttg taggtgaagg cttccaggc cagatgtgcc actgacttca acttgtagtt 420
 cacaaagagc tggggcagca tgaagaggaa accaaaggca tagaccccg tgcaggaagt 480
 gttgattaac caggagtacc agctcttata tttgatattc aggagtgaat agacagcacc 540
 35 cccgacacag agagggtaca gcaggtaga caagtacttc atggcctgag tatcgtactc 600
 ctcggttttc ctctcagatt cgctgtaagt gccaaactga aattcgggca tcaggcctct 660
 caaaaaata gtcattctca atgccttctt cactttccac agctcaatgg cggctccaac 720
 acccgccggg accagcacca gcaggctcgt ctgctcgtcc agcaggaaca gaaagatgac 780
 cagcgtgctg aagcagcgcc agagcactgc cttggtggac atgccgatca tgctcttctt 840
 40 cttcttccag aaactgatgt cattttttaa ggccaggaaa tcaaagagaa gatggaacgc 900
 tgcgacaaag aaggtcagcg ccaggaagta taagtggta tctacaaaaa ttcctttcac 960
 ctcacagca tctttctctg aaaacccgaa ctgctgcagg gactacacgg cgtcctgcat 1020
 gtggatccag aagcgcagcc gcccagtgac gaccttgcg taggacacgg tgaggggcag 1080
 45 ctcggtgggt gagcgggtta tgaccatcag gctcctcac cggttgctga gctgggtcgt 1140
 gaacaggatg ggcaggtaat gcacggtttt cccagctgg atcatcttca tgtaccgatg 1200
 cacatcgga ggcaggagg acccgtcaaa gacaaagtgt tccgccatca cgttcagcgc 1260
 cagccgcggt cgccagtggg aactggctc atccagggca ctgcgtcggc tcttctccgc 1320
 ctgcattctg tgtgtatcag actccccggg gagcagggtg atttcttctg gcttggggac 1380
 catgtagggt gtcagaggac tgaccagggt cacctgcttc ccgtcgtgcc acggcaggac 1440
 50 cccagcgtga tggaggaaag ttaggcata cagcgtccca ttgtttctcg ttttcttttg 1500
 tacagaaaca ttaactgtcc tttcaaattt ggactccaca tcaaagtctt ccacattcaa 1560
 gaccaggctg atgttgttct cagcaccagc gtgggacctc gtcgtggtgt acacgctcag 1620
 ctgcagcttg ggccgcgcgc ccaggtaggc ctggtgcag ttggcgtcgc cggagcacgc 1680
 55 gcgggtgtag acgatgccgt acatgaccca gcagggtgac accacgtaga ccacgaacac 1740
 gccaccacc aagctggtga aggagctgcg gcccc

<210> 30
 <211> 1546
 <212> DNA
 60 <213> Human

<400> 30

65 aaaataagta ggaatgggca gtgggtattc acattcacta caccttttcc atttgctaatt 60
 aaggccctgc caggctggga ggggaattgt cctgcctgct tctggagaaa gaagatattg 120

	acaccatcta	cgggcaccat	ggaactgctt	caagtgacca	ttctttttct	tctgcccagt	180
	atgtgcagca	gtaacagcac	aggtgtttta	gaggcagcta	ataattcact	tggtgttact	240
	acaacaaaac	catctataac	aacaccaaac	acagaatcat	tacagaaaaa	tggtgtcaca	300
5	ccaacaactg	gaacaactcc	taaaggaaca	atcaccaatg	aattacttaa	aatgtctctg	360
	atgtcaacag	ctactttttt	aacaagtaaa	gatgaaggat	tgaaagccac	aaccactgat	420
	gtcaggaaga	atgactccat	catttcaaac	gtaacagtaa	caagtgttac	acttccaaat	480
	gctgtttcaa	cattacaaag	ttccaaaccc	aagactgaaa	ctcagagttc	aattaaaaa	540
	acagaaatac	caggtagtgt	tctacaacca	gatgcatcac	cttctaaaac	tggtacatta	600
	acctcaatac	cagttaacaat	tccagaaaac	acctcacagt	ctcaagtaat	aggcactgag	660
10	ggtggaaaaa	atgcaagcac	ttcagcaacc	agccggtctt	attccagtat	tattttgccc	720
	gtgggttattg	ctttgattgt	aataacactt	tcagtatttg	ttctggtggg	tttgtaccga	780
	atgtgctgga	aggcgatcc	gggcacacca	gaaaaaggaa	atgatcaacc	tcagtctgat	840
	aaagagagcg	tgaagcttct	taccgttaag	acaatttctc	atgagtctgg	tgagcactct	900
	gcacaaggaa	aaaccaagaa	ctgacagctt	gaggaaattct	ctccacacct	aggcaataat	960
15	tacgcttaat	cttcagcttc	tatgcaccaa	gcgtggaaaa	ggagaaagtc	ctgcagaatc	1020
	aatcccgact	tccataacctg	ctgctggact	gtaccagacg	tctgtcccag	taaagtgatg	1080
	tccagctgac	atgcaataat	ttgatggaat	caaaaagaac	cccggggctc	tcctgttctc	1140
	tcacatttaa	aaattccatt	actccattta	caggagcgtt	cctaggaaaa	ggaattttag	1200
	gaggagaatt	tgtagcagct	gaatctgaca	gcccaggagg	tggtctcgct	gataggcatg	1260
20	actttcctta	atgtttaaag	ttttccgggc	caagaatttt	tatccatgaa	gactttccta	1320
	cttttctcgg	tgttcttata	ttacctactg	ttagtattta	ttgtttacca	ctatgttaat	1380
	gcagggaaaa	gttgacagtg	tattattaaa	tattaggtag	aaatcatacc	atgctacttt	1440
	gtacatatata	gtattttatt	cctgctttcg	tgttactttt	aataaataac	tactgtactc	1500
25	aatactctaa	aaatactata	acatgactgt	gaaaaaggca	aaaaaa		
	<210>	31					
	<211>	750					
	<212>	DNA					
	<213>	Human					
30							
	<400>	31					
	cacttgggca	ccccattttt	ctaaaaaaat	ggaaatctgg	agggcaaaaa	aggtgtgctg	60
35	aagggaagtg	cctctgatgg	cccaaaaacc	ttcttccaaa	ctagtgtagg	aatggaatgg	120
	atagcaaatg	gattcctttt	ggcctccttt	ggagcatgcc	ttccctatct	tatccttggc	180
	cccactaaag	cagaacgtta	cggatatttc	tgtttttgcc	attggatgcc	tatctggcca	240
	aacagccttt	ccctaattgg	aaaatgcagt	cctgtttaaa	acctttgatt	tacgactact	300
	tgtacatgct	tgctcattac	aattttgaca	ttttttacat	agtgaagacc	ccaaacatat	360
	cagtgaataa	tgacaagatc	ataaagaaca	gtatcatatt	attatttagt	cgcttttaca	420
40	gtggcagacc	aattttgaaa	tatctcattt	aaaactcaga	cccaattcac	tgagttatac	480
	ttttaatagc	ttcctcagca	cactatttcc	catgcattaa	atatgataaa	ataatctatc	540
	actgcccata	ggctctgtta	aaagggaagtc	tgaatacaga	gcccacaaca	ctaaaattgt	600
	ttttctagct	acaaagtata	gcacatcaaa	cacagacacg	atttggactc	cctgacaggt	660
	ggatttgaaa	acggtgttta	aagagaagag	aacattttta	cataaatgtc	attaagaatc	720
45	ccaaaggcct	tattttgtcac	caccgtcccg				
	<210>	32					
	<211>	1620					
	<212>	DNA					
50	<213>	Human					
	<400>	32					
	gcaattcccc	cctccacta	aacgactccc	agtaattatg	tttacaaccc	attggatgca	60
55	gtgcagccat	tcataagaac	cttgggtgcc	cagaaaaatc	tgctcttttt	ggtaccaaac	120
	ctgagggtctt	ttggaagata	atgtagaaaa	ccactaccta	ttgaaggcct	gttttggtca	180
	atctgtgcaa	actctgatga	tacctgcctt	atgtggattc	ttttccacac	tgctttcatt	240
	tttaagtata	aagacttaga	aaactagaat	aatgctttta	caaataatta	aaagtattgt	300
	atgtttctggg	tttttttctt	cttttttagaa	ccccgcctcc	atttaaaaaa	ttaaaaaaa	360
60	aaaaaaaaact	tttaacattt	aaaaaataaa	aattaacaaa	atttcactta	ttccaggaca	420
	cgctggcatt	tggaactcaat	gaaaagggca	cctaaagaaa	ataaggctga	ctgaatgttt	480
	tccataatttt	tcacacaata	acagtcctct	tctatccagc	ttgccttcca	tttatctcta	540
	gggttagctt	ttcaggcaac	atccttggtc	attgcccaga	aagtacctga	gctatcagtg	600
	attggaatgg	cacaggaaac	cgaatcacat	gggtgccctc	cccttggttt	tcaagtatct	660
65	tggaagtgtg	cacaaaaaatt	agggtcatgcc	ttcagtgctt	tggtctttta	acctaccctt	720
	tgacaatcag	gtgctaataga	ttgtatacta	ttaaaaccag	cacataagta	ttgtaaatgt	780

	gtgttcctcc	taggttgga	gaaatgtctt	tccttctatc	tgggtcctgt	taaagcgggt	840
	gtcagttgtg	tcttttcacc	tcgatttgtg	aattaataga	attgggggga	gaggaaatga	900
	tgatgtcaat	taagtttcag	gtttggcatg	atcatcattc	tcgatgatat	tctcactttg	960
	tcgcaaatct	gcccttatcg	taagaacaag	tttcagaatt	ttccctccac	tatacgactc	1020
5	cagtattatg	tttacaatcc	attggatgag	tgcagcatta	taagaccttg	gtgccagaa	1080
	aaatctgtcc	tttttggtac	caaacctgag	gtcttttgga	agataatgta	gaaaaccact	1140
	acctattgaa	ggcctgtttt	ggctaactcg	tgcaaaactc	gatgatacct	gcttatgtgg	1200
	attcttttcc	acactgcttt	catttttaag	tataaagact	tagaaaaacta	gaataatgct	1260
	tttacaata	attaaaagta	tgtgatgttc	tgggtttttt	ccttcttttt	agaaccctgt	1320
10	atttaacaa	gccttctttt	taagtcttgt	ttgaaattta	agtctcagat	cttctggata	1380
	ccaaatcaaa	aacccaacgc	gtaaaacagg	gcagtatttg	tgttcctaata	tttaaaaagc	1440
	tttatgtata	ctctataaat	atagatgcac	aaacaacact	tccccttgag	tagcacatca	1500
	acatacagca	ttgtacatta	caatgaaat	gtgtaactta	agggtattat	atatataaat	1560
15	acatatatac	ctttgtaacc	tttatactgt	aaataaaaaa	gttgcttttag	tcaaaaaaaa	1620
	<210> 33						
	<211> 2968						
	<212> DNA						
	<213> Human						
20	<400> 33						
	gaaaaagtag	aaggaaacac	agttcatata	gaagtaaaag	aaaaccctga	agaggaggag	60
25	gaggaggaag	agaggaaga	agaagatgaa	gaaagtgaag	aggaggagga	agaggaggga	120
	gaaagtgaag	gcagtgaagg	tgatgaggaa	gatgaaaagg	tgtcagatga	gaaggattca	180
	gggaagacat	tagataaaaa	gccaagtaaa	gaaatgagct	cagattctga	atatgactct	240
	gatgatgatc	ggactaaaga	agaaagggct	tatgacaaag	caaaacggag	gattgagaaa	300
	cggcgacttg	aacatagtaa	aaatgtaaac	accgaaaagc	taagagcccc	tattatctgc	360
30	gtacttgggc	atgtggacac	agggaaagaca	aaaattctag	ataagctccg	tcacacacat	420
	gtacaagatg	gtgaagcagg	tggtatcaca	caacaaattg	gggccaccaa	tgttcctctt	480
	gaagctatta	atgaacagac	taagatgatt	aaaaattttg	atagagagaa	tgtacggatt	540
	ccaggaatgc	taattattga	tactcctggg	catgaatcct	tcagtaatct	gagaaataga	600
	ggaagctctc	tttgtgacat	tgccatttta	gttgttgata	ttatgcatgg	tttggagccc	660
	cagacaattg	agtcctatcaa	ccttctcaaa	tctaaaaaat	gtcccttcat	tgttgcactc	720
35	aataagattg	ataggttata	tgattggaaa	aagagtcctg	actctgatgt	ggctgctact	780
	ttaaagaagc	agaaaaagaa	tacaaaagat	gaatttgagg	agcgagcaaa	ggctattatt	840
	gtagaatttg	cacagcaggg	tttgaatgct	gctttgtttt	atgagaataa	agatccccgc	900
	acttttgtgt	cttttggtacc	tacctctgca	catactgggt	atggcatggg	aagtctgatc	960
40	taccttcttg	tagagttaac	tcagaccatg	ttgagcaaga	gacttgcaca	ctgtgaagag	1020
	ctgagagcac	aggtgatgga	ggttaaagct	ctcccgggga	tgggcaccac	tatagatgtc	1080
	atcttgatca	atgggcggtt	gaagggaagg	gatacaatca	ttgttcctgg	agtagaaggg	1140
	cccattgtaa	ctcagattcg	aggcctcctg	ttacctcctc	ctatgaagga	attacgagtg	1200
	aagaaccagt	atgaaaagca	taaagaagta	gaagcagctc	aggggggtaa	gattcttgga	1260
45	aaagacctgg	agaaaacatt	ggctgggtta	cccctccttg	tggcttataa	agaagatgaa	1320
	atccctgttc	ttaaagatga	attgatccat	gagttaaagc	agacactaaa	tgctatcaaa	1380
	ttagaagaaa	aaggagtcta	tgtccaggca	tctacactgg	gttcttttga	agctctactg	1440
	gaatttctga	aaacatcaga	agtgccttat	gcaggaatta	acattggccc	agtgcataaa	1500
	aaagatgtta	tgaaggcttc	agtgatgttg	gaacatgacc	ctcagtatgc	agtaattttg	1560
50	gccttcgatg	tgagaattga	acgagatgca	caagaaatgg	ctgatagttt	aggagttaga	1620
	atttttagtg	cagaaattat	ttatcattta	tttgatgcct	ttacaaaata	tagacaagac	1680
	tacaagaaac	agaaacaaga	agaatttaag	cacatagcag	tatttccctg	caagataaaa	1740
	atcctccctc	agtacatttt	taattctcga	gtatccgatag	tgatgggggt	gacgggtgaa	1800
	gcaggtcagg	tgaacacagg	gacacccatg	tgtgtcccaa	gcaaaaattt	tgttgacatc	1860
55	ggaatagtaa	caagtattga	aataaaccat	aaacaagtgg	atgttgcaaa	aaaaggacaa	1920
	gaagtttgtg	taaaaaataga	acctatccct	ggtgagtcac	ccaaaatggt	tggaagacat	1980
	tttgaagcta	cagatattct	tgtagtaag	atcagccggc	agtccattga	tgactcaaa	2040
	gactggttca	gagatgaaat	gcagaagagt	gactggcagc	ttattgtgga	gctgaagaaa	2100
	gtatttgaaa	tcacttaatt	ttttcacatg	gagcaggaac	tggagtaaat	gcaatactgt	2160
60	gttgtaatat	cccaacaaaa	atcagacaaa	aaatggaaca	gacgtatttg	gacactgatg	2220
	gacttaagta	tggaagggaag	aaaaataggt	gtataaaatg	ttttccatga	gaaaccaaga	2280
	aacttacact	ggtttgacag	tggtcagtta	catgtcccca	cagttccaat	gtgcctgttc	2340
	actcacctct	cccttcccca	acccttctct	acttggctgc	tgttttaaag	tttgcccttc	2400
	cccaaatttg	gattttttatt	acagatctaa	agctctttcg	attttatact	gattaaatca	2460
65	gtactgcagt	atttgattaa	aaaaaaaaaa	gcagattttg	tgattcttgg	gacttttttg	2520
	acgtaagaaa	tacttcttta	tttatgcata	ttcttccac	agtgattttt	ccagcattct	2580
	tctgccatat	gccttttaggg	cttttataaa	atagaaaatt	aggcattctg	atatttcttt	2640

15

agctgctttg tgtgaaacca tgggtgtaaaa gcacagctgg ctgcttttta ctgcttgtgt 2700
 agtcacgagt ccattgtaat catcacaatt ctaaaccaaa ctaccaataa agaaaacaga 2760
 catccaccag taagcaagct ctggttaggt tccatgggta gtggtagctt ctctcccaca 2820
 agttgtcctc ctaggacaag gaattatctt aacaaactaa actatccatc acactacctt 2880
 5 ggtatgccag cacctgggta acagtaggag attttatata ttaatctgat ctgtttaatc 2940
 tgatcggttt agtagagatt ttatacat

<210> 34
 <211> 6011
 10 <212> DNA
 <213> Human

<400> 34

15

acggggcgcc ggacgacccg cacatcttat cctccacgcc ccactcgcac tccgagcggg 60
 accgccccgg actccccctc gggccggcca ctcgaggagt gaggagagag gccgcccggc 120
 20 cggtttgagc cgagcgagc acccccgcgc ccccgcgcca gaagtttggt tgaaccgggc 180
 tgcgggga ga aacttttttc ttttttcccc ctctcccggt agagtctctg gaggagagg 240
 ggaactcccc cggcccaagg ctcggtgggt cggggtcgcg cggccgcaga aggggagggg 300
 tccgccccgc aggggagggc ccccggggga cccgagaggg gggtagggac cgcgggctgc 360
 tgggtggggc ggggcagcgt gtgccccgcg caggggaggc gccgccccgc tcccggcccc 420
 25 gctgcgagga ggagggcgcg gcggcgagc aggatgtact tggtaggggg ggacaggggg 480
 ttggccgggt cggggcacct cctggtctcg ctgctggggc tggctgctgt gccggcgcg 540
 tccggcaccg gggcgctggt ctgctgccc tgtgacgagt ccaagtgcga ggagcccagg 600
 aaccgccccg ggagcatcgt gcaggggcgc tgcggctgct gctacacgtg cgcagccag 660
 ggaacgaga gctgcggcgg caccttcggg atttacggaa cctgcgaccg ggggctgcgt 720
 30 tgtgtcatcc gcccccgcct caatggcgac tccctcaccg agtacgaagc gggcgtttgc 780
 gaagatgaga actggactga tgaccaactg cttgggttta aaccatgcaa tgaaaacctt 840
 attgctggct gcaatataat caatgggaaa tgtgaatgta acaccattcg aacctgcagc 900
 aatccccctt agtttccaa tcagatatg tgcctttcag ctttaagag aattgaagaa 960
 gagaagccag attgtccaa ggccgctgt gaagtccagt tctctccacg ttgtcctgaa 1020
 35 gattctgttc tgatcgagg ttatgtctct cctggggagt gctgtccctt acccagccgc 1080
 tgcgtgtgca accccgcagg ctgtctgcgc aaagtctgcc agccgggaaa cctgaacata 1140
 ctagtgtcaa aagcctcagg gaagccggga gagtgtgtg acctctatga gtgcaaacca 1200
 gttttcggcg tggactgcag gactgtggaa tgcctactg ttcagcagac cgcgtgtccc 1260
 ccggacagct atgaaactca agtcagacta actgcagatg gttgctgtac ttgccaaca 1320
 40 agatgcgagt gtctctctgg cttatgtggt ttccccgtgt gtgaggtggg atccactccc 1380
 cgcatagtct ctggtggcga tgggacacct ggaaagtgt gtgatgtctt tgaatgtgtt 1440
 aatgatacaa agccagcctg cgtatttaac aatgtggaat attatgatgg agacatgttt 1500
 cgaatggaca actgtcgggt ctgtcgatgc caagggggcg ttgccatctg cttcacccgc 1560
 45 cagtgtgggt agtaaaactg cgagaggtac tacgtgcccc aaggagagtg ctgcccagtg 1620
 tgtgaagatc cagtgtatcc ttttaataat cccgctgggt gctatgcaa tggcctgatc 1680
 cttgcccacg gagaccggtg gcgggaagac gactgcacat tctgccagt cgtcaacgg 1740
 gaacgccact gcgttgcgac cgtctcgga cagacctgca caaacctgt gaaagtgcct 1800
 ggggagtggt gccctgtgtg cgaagaacca accatcatca cagttgatcc acctgcatgt 1860
 50 ggggagttat caaactgcac tctgacacgg aaggactgca ttaatggttt caaacgcgat 1920
 cacaatggtt gtcggacctg tcagtgcata aacaccagg aactatgttc agaacgtaaa 1980
 caaggctgca ccttgaactg tcccttcggt ttccctactg atgccccaaa ctgtgagatc 2040
 tgtgagtgc gcccaaggcc caagaagtgc agaccataa tctgtgaca gtattgtcca 2100
 cttgattgct ttcagaataa gcacggctgt gacatctgtc gctgtaagaa atgtccagag 2160
 55 ctctcatgca gtaagatctg ccccttgggt ttccagcagg acagtcacgg ctgtcttctc 2220
 tgcaagtgc gagaggctc tgcctcagct gggccaccca tctgtcggt cacttgtctc 2280
 accgtggatg gtcacatca taaaaatgag gagagctggc acgatgggtg ccgggaatgc 2340
 tactgtctca atggacggga aatgtgtgcc ctgacacct gcccggtgcc tgcctgtgcc 2400
 aacccacca ttcacctgg acagtgtgc ccatcatgtg cagatgactt tgtggtgcag 2460
 aagccagagc tcagtactcc ctccatttgc cagccccctg gaggagaata ctttgtgga 2520
 60 ggagaaacgt ggaacattga ctccgtgact cagtgcacct gccacagcgg acgggtgtctg 2580
 tgtgagacag aggtgtgccc accgctgctc tgcagaacc cctcacgcac ccaggattcc 2640
 tgtgtccac aggtgtacaga tcaacctttt cggccttcc tgtcccgcaa taacagccta 2700
 cctaattact gcaaaaaatga tgaaggggat atattcctg cagctgagtc ctggaagcct 2760
 65 gacgtttgta ccagctgcat ctgcattgat agcgtaatga gctgtttctc tgagtcctgc 2820
 ccttctgtat cctgtgaaag acctgtcttg agaaaaggcc agtggtgtcc ctactgcata 2880
 aaagacacaa ttccaaagaa ggtggtgtgc cacttcagtg ggaaggccta tgccgacgag 2940

	gagcgggtggg	accttgacag	ctgcacccac	tgctactgcc	tgcagggccca	gaccctctgc	3000
	tcgaccgtca	gctgcccccc	tctgccctgt	gttgagccca	tcaacgtgga	aggaagttgc	3060
	tgcccaatgt	gtccagaaat	gtatgtccca	gaaccaacca	atatacccat	tgagaagaca	3120
	aaccatcgag	gagaggttga	cctggagggt	cccctgtggc	ccacgcctag	tgaaaatgat	3180
5	atcgtccatc	tccctagaga	tatgggtcac	ctccaggtag	attacagaga	taacaggctg	3240
	cacccaagtg	aagattcttc	actggactcc	attgcctcag	ttgtggttcc	cataattata	3300
	tgctctctta	ttataatagc	attcctattc	atcaatcaga	agaaacagtg	gataccactg	3360
	ctttgctggt	atcgaacacc	aactaagcct	tcttccttaa	ataatcagct	agtatctgtg	3420
	gactgcaaga	aaggaaccag	agtccagggt	gacagttccc	agagaatgct	aagaattgca	3480
10	gaaccagatg	caagattcag	tggcttctac	agcatgcaaa	aacagaacca	tctacaggca	3540
	gacaatttct	accaaaccag	gtgaagaaag	gcaactagga	tgaggtttca	aaagacggaa	3600
	gacgactaaa	tctgctctaa	aaagtaaaact	agaattttgt	cacttgctta	gtggattgta	3660
	ttggattgtg	acttgatgta	cagcgctaag	accttactgg	gatgggctct	gtctacagca	3720
	atgtgcagaa	caagcattcc	cacttttccct	caagataact	gaccaagtgt	tttcttagaa	3780
15	ccaaagtttt	taaagtgtgt	aagatatatt	tgctgtgaag	atagctgtag	agatatttgg	3840
	ggtggggaca	gtgagtttgg	atggggaaaag	gggtgggagg	gtggtgttgg	gaagaaaaat	3900
	tggtcagctt	ggctcgggga	gaaacctggg	aacataaaaag	cagttcagtg	gcccagaggt	3960
	tatttttttc	ctattgctct	gaagactgca	ctgggtgtctg	caaagctcag	gcctgaatga	4020
	gcaggaaaca	aaaaaggcct	tgcgacccag	ctgccataac	caccttagaa	ctaccagacg	4080
20	agcacatcag	aaccttttga	cagccatccc	aggtctaaag	ccacaagttt	cttttctata	4140
	cagtcacaaac	tcgagtaggc	agtgaagaaag	ccagagaaat	gcgatagcgg	catttctcta	4200
	aagcgggtta	ttaaggatat	atacagttac	actttttgct	gcttttattt	tcttccaagc	4260
	caatcaatca	gccagttcct	agcagagtca	gcacatgaac	aagatctaag	tcatttcttg	4320
	atgtgagcac	tgagactttt	tttttttaca	acgtgacagg	aagaggaggg	agagggtgac	4380
25	gaacaccagg	catttccagg	ggctatatatt	cactgtttgt	tggtgctttg	ttctgttata	4440
	ttgttggttg	ttcatagttt	ttgttgaagc	tctagcttaa	gaagaaactt	tttttaaaaa	4500
	gactgttttg	ggattctttt	tccttattat	atactgattc	tacaaaaatg	aaactacttc	4560
	attttaattg	tatattattc	aagcaccctt	gttgaagctc	aaaaaaaaat	atgcctcttt	4620
	aaacttttag	aattatagga	gtatttatgt	aactatctta	tgcttcaaaa	aacaaaagta	4680
30	tttgtgtgca	tgtgtatata	atatatatat	atacatatat	atttatacac	atacaattta	4740
	tgttttcctg	ttgaatgtat	ttttatgaga	ttttaaccag	aacaaaggca	gataaacagg	4800
	cattccatag	cagtgtcttt	gatcacttac	aaattttttg	aataacacaa	aatctcattc	4860
	tacctgcagt	ttaattggaa	agatgtgtgt	gtgagagtat	gtatgtgtgt	gtgtgtgtgt	4920
	gtgtgtgcgc	gcgcacgcac	gccttgagca	gtcagcattg	cacctgctat	ggagaagggt	4980
35	attcctttat	taaaatcttc	ctcatttgga	tttgctttca	gttggttttc	aatgtgtctc	5040
	ctggccagag	acattgatgg	cagttcttat	ctgcactcact	aatcagctcc	tggttttttt	5100
	tttttttttt	tcaaacaatg	gtttgaaaca	actactggaa	tattgtccac	aataagctgg	5160
	aagtttggtg	tagtatgcct	caaataatac	tgactgtata	ctatagtggg	aacttttcaa	5220
	acagccctta	gcacttttat	actaattaac	ccatttggtc	attgagtttt	cttttaaaaa	5280
40	tgcttggtgt	gaaagacaca	gatacccgat	atgcttaacg	tgaaaagaaa	atgtgttctg	5340
	ttttgtaaag	gaactttcaa	gtattgttgt	aaatacttgg	acagaggttg	ctgaacttta	5400
	aaaaaaatta	atttattatt	ataatgacct	aatttatata	tctgaagatt	aaccattttt	5460
	ttgtcttaga	atatcaaaaa	gaaaaagaaa	aaggtgttct	agctgtttgc	atcaaaaggaa	5520
45	aaaaagattt	attatcaagg	ggcaatattt	ttatcttttc	caaaataaat	ttgttaatga	5580
	tacattacaa	aaatagattg	acatcagcct	gattagtata	aattttgttg	gtaattaatc	5640
	cattctgggc	ataaaaagtc	tttatcaaaa	aaaattgtag	atgcttgctt	tttgtttttt	5700
	caatcatggc	catattatga	aaataactaac	aggatatagg	acaagggtga	aattttttta	5760
	ttattatttt	aaagatatga	tttatcctga	gtgctgtatc	tattactctt	ttactttggt	5820
	tcctgttgtg	ctcttgtaaa	agaaaaatat	aatcttctga	agaataaaat	agatatatgg	5880
50	cacttggagt	gcacatagat	tctacagttt	gtttttgttt	tcttcaaaaa	agctgtaaga	5940
	gaattatctg	caacttgatt	cttggcagga	aataaacatt	ttgagttgaa	atcaaaaaaa	6000
	aaaaaaaaaa	a					
55	<210>	34a					
	<211>	1036					
	<212>	DNA					
	<213>	Human					
60	<400>	34a					
	mylvagdrql	agcghllvsl	lgllllpars	gtralvclpc	deskceepn	rpgsivqgvc	60
	gccytcasgg	nescggtfgi	ygtcdrqlrc	virpplngds	lteyeagvce	denwtddql	120
65	gfkpcnenli	agcniingkc	ecntirtcsn	pfefpsqdmc	lsalkrieee	kpdcskarce	180
	vqfSprcped	svliegyapp	geccplpsrc	vcnpagclrk	vcqpgnlnil	vskasgkpgc	240

5 ccdlyeckpv fgvdcrvec ptvqqtacpp dsyetqvrllt adgcctlptr cecslgclcgf 300
 pvcevgstpr ivsrgdgtpg kccdvfecvn dtkpacvfnn veyydgdmfrr mdncrfrcrq 360
 ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420
 ctfcqcvnge rhcvatvcgq tctnpvkvpq eccpvceep iitvdppacg elsnctllrk 480
 dcingfkrdh ngcrtcqcin tqelcserkq gctlncpfpg ltdaqnceic ecrprpkkr 540
 piicdkycpl gllknkhgdc icrckkcpel scskicplgf qgdshgcllc kcreasasag 600
 ppilsgtclt vdghhhknee swhdgcrecy clngremcal itcpvpacgn ptihpgqccp 660
 scaddfvvqk pelstpsich apggeyfvge etwnidsctq ctchsgrvlc etevcppllc 720
 10 qmpsrtdqsc cpqctdqfpr pslsrnnsvp nyckndegdi flaaeswkpd vctscicids 780
 viscfesescp svscerpvlr kgqccpycik dtipkkvvch fsgkayadee rwdldscethc 840
 yclqgqtlcs tvscpplpcv epinvegsc pmcpemyvpe ptnipiektn hrgevdlevp 900
 lwptpsendi vhlprdmghl qvdyrdnrhl psedssldsi asvvvpiic lsiiiaflfi 960
 nqkqwipll cwyrtpkps slnnqlvsvd ckkgrtrvqd ssqrmlriae pdarfsgfys 1020
 15 mqkqnhlqad nfyqtv

<210> 35
 <211> 716
 <212> DNA
 20 <213> Human

<400> 35

25 gcagtagctg gagtgcctcg cagggggaaa gcgaaccggg ccctgaagtc cggggcagtc 60
 acccggggct cctgggcccgc tctgccgggc tggggctgag cagcgatcct gctttgtccc 120
 agaagtcagc agggatcagc cccagaacac accctcctcc ccgggacgcc gcagctttct 180
 ggaggctgag gaaggcatga agagtgggct ccacctgctg gccgactgag aaaagaattt 240
 30 ccagaactcg gtcctatattt acagattgag aaactatggt tcaagaagag aggacggggc 300
 ttgagggaat ctcttgattc tccttatatg acctcaaact gaccatacta aacagtgtag 360
 aaggctcttt taaggctcta aatgtcaggg tctcccaccc cctgatgcct gacttgtaca 420
 gtcagtgtgg agtagacggg ttctccacc cagggttgac tcagggggat gatctgggtc 480
 ccattctggt cttaagaccc caaacaaggg ttttttcagc tcaggatct ggagcctcta 540
 35 tctgttagt gtcgtaacct ctgtgtgcct cccgttaacc catctgtcca gtgagctcag 600
 ccccatcca cctaacaggg tggccacagg gattactgag ggttaagacc ttagaactgg 660
 gtctagcacc cgataagagc tcaataaatg ttgttccttt ccacatcaaa aaaaaa

<210> 36
 <211> 395
 40 <212> DNA
 <213> Human

<400> 36

45 ccaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60
 aaaagctatg atttgatttc caacttttaa acattgcatg tcctttgcc a ttactacat 120
 tctccaaaaa aaccttgaaa tgaagaaggc cacccttaa atacttcaga ggctgaaaa 180
 atgattatta cattggaatc ctttagccta tgtgatattt cttaacttt gcactttcac 240
 50 gccagtaaa accaaagtca gggaaccaa tgatctttta caaatgtta aaaccctaat 300
 tgcagttcct tttttaaat attttaaga ttacttaaca acattagaca gtgcaaaaaa 360
 agaagcaagg aaagcattct taattctacc atcct

<210> 37
 <211> 134
 55 <212> DNA
 <213> Human

<400> 37

60 ccctcgagcg gccgcccggg caggtagctt taccaccgaa ttgttcactt gactttaaga 60
 aaccataaaa gctgcctggc tttcagcaac aggcctatca acaccatggt gacttccat 120
 aaggacacc gtgt

<210> 38
 65 <211> 644
 <212> DNA

<213> Human

<400> 38

```

5  aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcgggc gaggtagagg 60
   cagtggcgct tgagttgggtc gggggcagcg gcagatttga ggcttaagca acttcttcg 120
   gggaagagtg ccagtgacagc cactgttaca attcaagatc ttgatctata tccatagatt 180
   ggaatattgg tgggccagca atcctcagac gcctcactta ggacaaatga ggaaactgag 240
   gcttggtgaa gttacgaaac ttgtccaaaa tcacacaact tgtaaagggc acagccaaga 300
10  ttcagagcca ggctgtaaaa attaaaatga acaaattacg gcaaagtttt aggagaaaaga 360
   aggatgttta tgttccagag gccagtcgtc cacatcagtg gcagacagat gaagaaggcg 420
   ttcgcaccgg aaaatgtagc ttcccgggta agtaccttgg ccatgtagaa gttgatgaat 480
   caagaggaat gcacatctgt gaagatgctg taaaaagatt gaaagctgaa aggaagttct 540
   tcaaaggctt ctttggaaaa actggaaaaga aagcagttaa agcagtttct gtgggtctaa 600
15  gcagatggac tcagaggttg tggatgaaaa actaaggacc tcatt

```

<210> 39

<211> 657

<212> DNA

20 <213> Human

<400> 39

```

25  ctttttgttt gggttttcca atgtagatgt ctcagtgaaa tgtgcagata tactttgttc 60
   cttatatggt caccagtgtt aattatggac aaatacatta aaacaagggt tcctggccca 120
   gcctcccatc taatctcttt gatactcttg gaatctaagt ctgaggagcg atttctgaat 180
   tagccagtgt tgtaccaact ttctgttagg aattgtatta gaataacctt tctttttcag 240
   acctgctcag tgagacatct tggggaatga agtaggaaaa tagacatttg gtggaaaaaac 300
   agcaaaatga gaacattaaa aagactcatt caagtatgag tataaagggc atggaaattc 360
30  ttgtcctttg agcaaaatga gaagaaaaaa ttctgctcag cagtattcac tgtgttaaga 420
   ttttttgttt ttacacgaa tggaaaaatg atgtgtaagt ggtatagatt ttaatcagct 480
   aacagtcact ccagagattt tgatcagcac caattcctat agtagtaagt atttaaaagt 540
   taagaaatac tactacattt aacattataa agtagagttc tggacataac tgaaaattag 600
   atgtttgctt caatagaaat ttgttccac ttgtattttc aacaaaatta tcggaac

```

<210> 40

<211> 1328

<212> DNA

<213> Human

40

<400> 40

```

45  acaatttttaa aataactagc aattaatcac agcatatcag gaaaaagtac acagtgagtt 60
   ctggttaggtt tttgtaggct cattatgggt agggctcgta agatgtatat aagaacctac 120
   ctatcatgct gtatgtatca ctcattccat ttcatgttc catgcatact cgggcatcat 180
   gctaataatgt atcctttttaa gcactctcaa ggaaacaaaa gggcctttta tttttataaa 240
   ggtaaaaaaa attcccaaaa tattttgcac tgaatgtacc aaaggtgaag ggacattaca 300
   atatgactaa cagcaactcc atcacttgag aagtataata gaaaatagct tctaaatcaa 360
   acttccttca cagtgccgtg tctaccacta caaggactgt gcatctaagt aataattttt 420
50  taagattcac tatatgtgat agtatgatag gcatttattt aaaatgcatt agactctctt 480
   ccatccatca aatactttac aggatggcat ttaatacaga tatttcgtat ttccccact 540
   gctttttatt tgtacagcat cattaaacac taagctcagt taaggagcca tcagcaacac 600
   tgaagagatc agtagtaaga attccatttt ccctcatcag tgaagacacc acaaattgaa 660
   actcagaact atatttctaa gcctgcattt tcaactgatgc ataattttct tagtaatat 720
55  aagagacagt ttttctatgg catctccaaa actgcatgac atcactagtc ttacttctgc 780
   ttaattttat gagaagggtat tcttcatttt aattgctttt gggattactc cacatctttg 840
   tttatttctt gactaatcag attttcaata gagtgaagtt aaattggggg tcataaaagc 900
   attgatttga catatgggtt gccagcctat gggtttacag gcattgcccc aacatttctt 960
   tgagatctat atttataagc agccatggaa ttccatttat gggatgttgg caatcttaca 1020
60  ttttatagag gtcatatgca tagttttcat aggtgttttg taagaactga ttgctctcct 1080
   gtgagtttaag ctatgtttac tactgggacc ctcaagagga ataccactta tgttacactc 1140
   ctgcactaaa ggcacgtact gcagtgtaga gaaatgttct gaaaaagggt tatagaaatc 1200
   tggaaataag aaaggaagag ctctctgtat tctataattg gaagagaaaa aaagaaaaac 1260
   ttttaactgg aaatgttagt ttgtacttat tgatcatgaa tacaagtata tatttaattt 1320
65  tgaaaaaa

```

<210> 41
<211> 987
<212> DNA
<213> Human

5

<400> 41

aacagagact ggcacaggac ctcttcattg caggaagatg gtagttagg caggtaacat 60
tgagctcttt tcaaaaaagg agagctcttc ttcaagataa ggaagtggta gttatgggtg 120
10 taacccccgg ctatcagtcg ggatggttgc caccctcctt gctgtaggat ggaagcagcc 180
atggagtggg agggaggcgc aataagacac ccctccacag agcttggcat catgggaagc 240
tggttctacc tcttcctggc tcctttgttt aaaggcctgg ctgggagcct tccttttggg 300
tgtctttctc ttctccaacc aacagaaaag actgctcttc aaagggtggag ggtcttcatg 360
aaacacagct gccaggagcc caggcacagg gctggggggc tggaaaaagg agggcacaca 420
15 ggaggaggga ggagctggta gggagatgct ggctttacct aaggctctga aacaaggagg 480
gcagaatagg cagaggcctc tccgtcccag gccattttt gacagatggc gggacggaaa 540
tgcaatagac cagcctgcaa gaaagacatg tgttttgatg acaggcagtg tggccgggtg 600
gaacaagcac aggccttggg atccaatgga ctgaatcaga accctaggcc tgccatctgt 660
cagccgggtg acctgggtca attttagcct ctaaaagcct cagtctcctt atctgcaaaa 720
20 tgaggcttgt gatacctgtt ttgaagggtt gctgagaaaa ttaaagataa gggatatcaa 780
aatagtctac ggcataacca ccctgaacgt gcctaattct gtaagctaag cagggtcagg 840
cctggttagt acctggatgg ggagagtatg gaaaacatac ctgcccgcag ttggagttgg 900
actctgtctt aacagtagcg tggcacacag aaggcactca gtaaatactt gttgaataaa 960
tgaagtagcg atttggtgtg aaaaaaa

25

<210> 42
<211> 956
<212> DNA
<213> Human

30

<400> 42

cggacgggtg ggcggacgcg tgggtgcagg agcaggggcg ctgccgactg ccccaacca 60
ggaaggagcc cctgagtcg cctgcgcctc catccatctg tccggccaga gccggcatcc 120
35 ttgcctgtct aaagccttaa ctaagactcc cgccccgggc tggccctgtg cagaccttac 180
tcaggggatg ttaccttgtt gctcgggaag ggaggggaag gggccgggga gggggcacgg 240
caggcgtgtg gcagccacac gcaggcgcc agggcggcca gggacccaaa gcaggatgac 300
cacgcacctc cagccactg cctccccga atgcatttgg aaccaaagtc taaactgagc 360
tcgcagcccc cgcgccctcc ctccgcctcc catcccgctt agcgctctgg acagatggac 420
40 gcaggccctg tccagcccc agtgcgctcg ttccggtccc cacagactgc cccagccaac 480
gagattgtct gaaaccaagt caggccaggt gggcggaaca aagggccagg tgcggcctgg 540
ggggaacgga tgcctcgagg actggactgt tttttcaca catcgttgcc gcagcgggtg 600
gaaggaaaag cagatgtaaa tgatgtgttg gtttacaggg tatatttttg ataccttcaa 660
tgaattaatc cagatgtttt acgcaaggaa ggacttacct agtattactg ctgctgtgct 720
45 tttgatctct gcttaccgtt caagaggcgt gtgcaggccg acagtcggtg accccatcac 780
tcgcaggacc aagggggagg ggactgctgg ctacgcccc gctgtgtcct ccctccctc 840
ccttccttgg gcagaatgaa ttcgatgcgt attctgtggc cgccatctgc gcagggtgg 900
ggtattctgt catttacaca cgtcgttcta attaaaaagc gaattatact ccaaaa

50

<210> 43
<211> 536
<212> DNA
<213> Human

55

<400> 43

aaataaacac ttccataaca ttttgttttc gaagtctatt aatgcaatcc cacttttttc 60
cccctagttt ctaaatgtta aagagagggg aaaaaaggct caggatagtt ttcacctcac 120
60 agtggttagct gtcttttatt ttactcttgg aaatagagac tccattaggg ttttgacatt 180
ttgggaaccc agttttacca ttgtgtcagt aaaacaataa gatagtttga gagcatatga 240
tctaaataaa gacatttgaa gggttagttt gaattctaaa agtaggtaat agccaaatag 300
cattctcctc ccttaacaga caaaaactta tttgtcaaaa gaattagaaa aggtgaaaat 360
attttttcca gatgaaactt gtgccacttc caattgacta atgaaatata aggagacaga 420
ctggaaaaag tgggttatgc cacctttaaa accctttctg gtaaatatta tggtagctaa 480
65 aggggtggtt ccccgccacc tggacctgga caggtagggg tccgtggtta accagt

<210> 44
<211> 1630
<212> DNA
<213> Human

5
<400> 44

10
ggggaggggac gagtatggaa ccctgaaggt agcaagtcca ggcactggcc tgaccatccg 60
gctccctggg caccaagtcc caggcaggag cagctgtttt ccatcccttc ccagacaagc 120
tctattttta tcacaatgac ctttagagag gtctcccagg ccagctcaag gtgtcccact 180
atccccctcg gagggaaagag gcaggaaaat tctccccggg tccctgtcat gctactttct 240
ccatcccagt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300
gtgattttccc ttaggccccag gacttgggcc tccagctcat ctgttccttc tgggcccatt 360
catggcaggt tctgggctca aagctgaact ggggagagaa gagatacaga gctaccatgt 420
15 gactttacct gattgccctc agtttggggt tgcttatttg gaaagagaga gacaaagagt 480
tacttggttac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540
gacaggattg gctcagatga cccctgaggg ctcttcagct cttgaaatgc attccatgat 600
attaggaagt cgggggtggg tgggtggtgg gggctagtgt ggtttgaatt taggggccga 660
tgagcttggg tacgtgagca ggggtttaag ttagggtctg cctgtatttc tgggtcccctt 720
20 ggaaatgtcc ccttcttcag tgtcagacct cagtcaccag gtccatatcg tgcccagaaa 780
agtagacatt atcctgcccc atcccttccc cagtgcactc tgacctagct agtgccctgt 840
gcccagtgac ctgggggagc ctggctgcag gccctcactg gttccctaaa ccttgggtggc 900
tgtgattcag gtccccaggg gggactcagg gaggaatatg gctgagttct gtagtttcca 960
gagttggctg gtagagcctt cttagaggttc agaataatag cttcaggatc agctgggggt 1020
25 atggaattgg ctgaggatca aacgtatgta ggtgaaagga taccaggatg ttgctaaagg 1080
tgaggggacag tttgggtttg ggacttacca ggggtgatgt agatctggaa cccccaagt 1140
aggctggagg gagttaaggt cagtatggaa gatagggttg ggacagggtg ctttggaatg 1200
aaagagtgac ctttagagggc tccttgggcc tcaggaatgc tcctgctgct gtgaagatga 1260
gaaggtgctc ttactcagtt aatgatgagt gactatattt accaaagccc ctacctgctg 1320
30 ctgggtccct tgtacacag gagactgggg ctaaggggcc ctcccaggga agggacacca 1380
tcaggccctc ggctgaggca gtagcataga ggatccattt ctacctgcat ttcccagagg 1440
actagcagga ggcagccttg agaaaccggc agttcccaag ccagcgctg gctgttctct 1500
cattgtcact gccctctccc caacctctcc tctaaccac tagagattgc ctgtgtcctg 1560
35 cctcttgcct cttgtagaat gcagctctgg ccctcaataa atgcttctct cattcatctg 1620
caaaaaaaaa

<210> 45
<211> 169
<212> DNA
40 <213> Human

<400> 45

45
tcttttgcct ttagcttttt atttttgtat taacaggagt cttattacac ataggtctga 60
taaaactggg ttatgatctt cagtctgatt ccagtgtgc ataactagat aacgtatgaa 120
ggaaaaacga cgacgaacaa aaaagtaagt gcttggaaaga cttagttaga

<210> 46
<211> 769
50 <212> DNA
<213> Human

<400> 46

55
tgcaggctcat atttactatc ggcaataaaa ggaagcaaa cagtattaa cagcgggtgga 60
atttgcgct ttcacttttt ataaagtgc acataaaatg tcatatttcc aaatttaaaa 120
acataactcc agttcttacc atgagaacag catggtgatc acgaaggatc ttcttgaaa 180
aaacaaaaac aaaaacaaaa aacaatgatc tcttctgggt atcacatcaa atgagataga 240
aaggtgtact aggcaatctt agagatctgg caacttattt tatatataag gcatctgtga 300
60 ccaagagacg ttatgaatta aatgtacaaa tgtattatgt ataaatgtat taaatgcaag 360
cttcatataa tgacaccaat gtctctaagt tgctcagaga tcttgactgg ctgtggccct 420
ggccagctcc tttcctgata gctctgattt gccttcatat ataggcagct cctgatcatc 480
catgccagtg aatgagaaaa caagcatgga atataataac ttttaacatta aaaaatgttt 540
tattttgtaa taaaatcaaa ttcccatgt aaaccttcaa aaactttgca gaatgagggt 600
65 ttgatatatg tgtacaagta gtaccttctt agtgcaagaa aacatcatta tttctgtctg 660
cctgcctttt tgttttttaa aatgaagact atcattgaaa caagtttgtc ttcagtatca 720

ggacatgttg acggagagga aaggtaggaa agggtaggg atagaagcc

<210> 47
 <211> 2529
 <212> DNA
 <213> Human

<400> 47

10 tttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatacac tttcacaaca 60
 gtgaaaatta gtgactggtt aagggtgtgc actgtacata tcatcatttt ctgactgggg 120
 tcaggacctg gtcctagttc acaaggggtg caggagggagg gtggaggcta agaacacaga 180
 aaacacacaa aagaaaggaa agctgccttg gcagaaggat gaggtggtga gcttgccgag 240
 ggatgggtggg aagggggctc cctgttgggg ccgagccagg agtcccaagt cagctctcct 300
 15 atttggccag cctggcttta ctaacaggtt ccagagtgcc ctctgttgcc tgagctctcc 420
 gccttactta gctcctggca gaggttgagt ggggacctac gaggttcaaa atcaaattgc 360
 atttggccag aatgttttaa atctatcagg cactactata agctgggtgt ttcttctctac 480
 tgggctcact ccatttcatt gaagagtcca aatgattcat tttcctaccc acaacttttc 480
 attattcttc tggaaaccca tttctgttga gtccatctga cttaagtcct ctctccctcc 540
 actagttggg gccactgcac tgaggggggt cccaccaatt ctctctagag aagagacact 600
 20 ccagaggccc ctgcaacttt gcggatttcc agaaggtgat aaaaagagca ctcttgagtg 660
 ggtggccagg aatgttttaa atctatcagg cactactata agctgggtgt ttcttctctac 720
 caagtggatt cggcatatga accacctact caatacttta tattttgtct gtttaaacac 780
 tgaactcttg tgttgacagg tacaaggag aagagatggg gactgtgaag aggggagggc 840
 ttccctcctc ttccctcaaga tctttgttcc cataaactat gcagtcataa ttgagaaaaa 900
 25 gcaatagatg gggcttccta ccatttgttg gttattgtcg gggtagcca ggagcagtgt 960
 ggtgggcaaa gtaggagaga ggccagagg aaagccatc tccctccagc tttgggtctc 1020
 ccagaaagag gctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080
 aggtgaacag tcctacctgc ttggtacat agtccctcaa taagattcag aggaagaagc 1140
 ttatgaaact gaaaaatcaa tcaaggtatt gggagaata atttcccctc gattccacag 1200
 30 gaggggaagc cacacaatat cattgtgctg gggctcccca aggcctgccc acctggcttt 1260
 acaaatcctc aggggttgcc tgcttgccag tcacatgctt ccctggtttt agcacacata 1320
 caaggagttt tcagggaact ctatcaagcc ataccaaaat cagggtcaca tgtgggttcc 1380
 ccctttcctt gcctcttcat aaaagacaac ttggcttctg aggatgggtg tcttttgcac 1440
 gcagttgggc tgacctgaca aagcccccag tttcctgttg caggttctgg gagaggatgc 1500
 35 attcaagctt ctgcagccta ggggacagg ctgcttgctt agttattact gcctcgagc 1560
 tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagtctcag 1620
 ctctcgccagt attctcggtt gtatgttctc tggcagagag aggcagatga acatagtttt 1680
 agggagaaag ctgatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740
 40 tgcagggaaa ccaggaagtc attcaagttg ttctctgagg ccaagacac tgagcacagc 1800
 ccagagccaa taaaagatct ttgagtctct ggtgaattca cgaagtgaac ccagctttag 1860
 ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920
 gggggagtggt gaggggaagg aaagagaaca gagcggcact gggatttgaa aggggaacct 1980
 ctctatctga ggagccccc ctggcttcag aagcaactta ccaaggggta tttaaagaca 2040
 45 tgaaaatttc cagaaatacc atttgggtga tcccttgggt tctgtaatat taaactcagg 2100
 tgaattata ctctgacagt ttctctcttt ctgctcttcc cctctgcaga gtcaggacct 2160
 gcagaactgg ctgaaacaag atttcatggt gtcacccatg agagatgact caatgccaag 2220
 gcctgaagtt atagagtgtt tacagcgggt gcgatattca ggggtcatcg ccaactggtc 2280
 tcgagttcca aagctctgat gaagaaacaa gactccttga tgtgttactg atcccactga 2340
 50 ttccaggagt caagattagc cagggaagcca aacaccagga gttgggggtg cacgtcacca 2400
 gtccagagcc ctgccacgga tgtacgcagg agcccagcat taggcaatca ggagccagaa 2460
 catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacatacct 2520
 ggggtgtcc

<210> 48
 <211> 1553
 <212> DNA
 <213> Human

<400> 48

60 tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatatatatt 60
 ttcatatata tatatacata catatataaa ggaaacaatt tgcaaattha cacacctgac 120
 aaaaccatat atacacacat atgtatgcat acacacagac agacacacac acccgaagct 180
 ctagccaggc ccgtttttcca tccctaagta ccattctctc atttgggccc ttctaggggt 240
 65 ggggccctga gcttggtttg tagaagtttg gtgctaatat aaccatagct ttaatcccca 300
 tgaaggacag ttagacctc atctttgtct gctcccgcgt gcctttcagt tttacgtgat 360

5 ccatcaagag ggctatggga gccaaagtga caccgggggat tgaggctaat tcacctgaac 420
 tcgaaaacag cgcccagctt cctcaccgca ggcacgcgtc ttttcttttt ttttcctcga 480
 gacggagtct cgctgtgttg cccaggctgg agtgcagtgg caccgtctcg gctcactgca 540
 agctccacct cctggattca taccattctc ctgcttcagc cttccgagta gctgggacta 600
 taggtgccaa ccactacgcc tagctaattt tttttgtat ttttagtaga gacagggttt 660
 caccgtgtta gccaggatgg tctcgtcctg actttgtgat cgcgccgct cgccctccca 720
 aagtgtggg attacaggcg tgagccacca cacctggccc cggcacgtat cttttaagga 780
 atgacaccag ttcctggctt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840
 10 agacaggagg gtggtggcag caacactgca gctgcttctg gatgctgctg ggggtgctctc 900
 cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960
 acttcagtgg tgcacctgga tgggtggaagc cagccttttg ggcaggaaac cagctcagag 1020
 aggtactacca gctcagctgc tggcaggagc caggtattta cagccataat gtgtgtaaag 1080
 aaaaaacacg ttctgcaaga aactctccta cccgctcggg agactggggc tccttgcttg 1140
 ggatgagctt cactcaacgt ggagatggtg gtggactggt ccctgaaaag cgggccttgc 1200
 15 agggccaagt gaggtcctca ggtcctaac ccagtggccc tctgaaaggg ggtgtgcagg 1260
 cgaggggagc aggaggcttc tctctagtcc ctttggaggc tttggctgag agaagagtga 1320
 gcagggagct gggaatggtc caggcaggga agggagctga agtgattcgg ggctaagcc 1380
 tcagatcgat gtatttctct ccctggtctc ccggagccct cttgtcaccg ctgctgccct 1440
 gcaggaggcc catctcttct gggagcttat ctgacttaac ttcaactaca agttcgtct 1500
 20 tacgagaccg ggggtagcgt gatctctgct tccctgagc gcctgcacgg cag

<210> 49

<211> 921

<212> DNA

25 <213> Human

<400> 49

30 ctgtggtccc agctactcag gaggtgagg cgggaggatt gcttgagccc aggagtggga 60
 tgttgcaagt agccaagatc gcaccattgc cctccactct gggccacgga gcaataccct 120
 gtctcagaaa acaacaaca aaaaagcagaa acgctgaagg ggtcggttta cgggaaaacc 180
 gcctgtcaga acacttggtt actcctaccc cagatcagtg gacctgggaa tgagggttgg 240
 tcccgggagg cttttctcca agctgttgcc accagaccgg ccattgggaac cctggccaca 300
 35 gaagcctccc ggggagtgag ccagagcctg gaccgctgtg ctgatgtgtc tggggtggag 360
 ggagggtggg gagtgtgcaa ggggtgtgtg gtgccgggg ggtgttcag ggcaagcatg 420
 tgcgtgcctg tgtgtgtgct tgccctccc ctgcagccgt cgggtgtatc tccctccagc 480
 cccttcgcca ccttctgagc attgtctgtc cacgtgagac tgcccagaga cagcagagct 540
 ccacgtggtt ttaaggggag acctttccct ggacctgggg gtctcgccgt atctcatgac 600
 40 caggtgctaa atgaccggac atgcatcacc tgcctttcga tgaccaacct ccctgtcccc 660
 gtcccgtgta cctgcccccg tggcgtctca cggatgatgc tgctcctgac attggtgttc 720
 actgtagcaa actaattct ggatgggaat tttcatgtac atgtgtggca tgtggaaaat 780
 ttcaaataaa atggacttga tttagaaagc caaaaagctg tgtggtcctt ccagcacgga 840
 tactttgacc tcttgccctac aaccccttcc ttgggtccga ggctggtagc tttgttccact 900
 45 tcagatgggt gggggcgggt g

<210> 50

<211> 338

<212> DNA

50 <213> Human

<400> 50

55 atgatctatc tagatgccct accgtaaaat caaaacacaa aaccctactg actcattccc 60
 tcccttcag atattacccc atttctctac tcccattgt agccaaactt tccaaaaatt 120
 catgttctgt cttcatttcc tcatgttcaa cccaccctgt cttagctacc accctcagt 180
 aacgacctag cctgggtaga acaaatgtc agcatgatac catactcaat gatccttcgt 240
 cactgttgtc attgtcatca ttccatggcc ttactttccc tctcagcgcc atttgctaca 300
 gtaagaaact ttctttcttg aattcttggg tctcttgg

60 <210> 51

<211> 1191

<212> DNA

<213> Human

65 <400> 51

5 ctagcaagca ggtaaacgag ctttgtacaa acacacacag accaacacat ccggggatgg 60
 ctgtgtgttg ctagagcaga ggctgattaa acactcagtg tggtggctct ctgtgccact 120
 cctggaaaat aatgaattgg gtaaggaaca gttaataaga aaatgtgcct tgctaactgt 180
 gcacattaca acaaagagct ggcagctcct gaaggaaaag ggcttgtgcc gctgccgttc 240
 aaacttgtca gtcaactcat gccagcagcc tcagcgtctg cctccccagc acaccctcat 300
 tacatgtgtc tgtctggcct gatctgtgca tctgctcgga gacgtcctg acaagtcggg 360
 aatttctcta tttctccact ggtgcaaaga gcggatttct ccctgcttct cttctgtcac 420
 ccccgctcct ctccccagg aggtccttg atttatggta gctttggact tgcttccccg 480
 tctgactgtc cttgacttct agaatggaag aagctgagct ggtgaaggga agactccagg 540
 10 ccatcacaga taaaagaaaa atacagggaag aaatctcaca gaagcgtctg aaaatagagg 600
 aagacaaaat aaagcaccag catttgaaga aaaaggcctt gagggagaaa tggcttctag 660
 atggaatcag cagcggaaaa gaacagggaag agatgaagaa gcaaaatcaa caagaccagc 720
 accagatcca ggttctagaa caaagtatcc tcaggcttga gaaagagatc caagatcttg 780
 aaaaagctga actgcaaatc tcaacgaagg aagaggccat tttaaagaaa ctaaagtcaa 840
 15 ttgagcggac aacagaagac attataagat ctgtgaaagt ggaaagagaa gaaagagcag 900
 aagagtcaat tgaggacatc tatgctaata tccctgacct tccaaagtcc tacatacctt 960
 ctagggttaag gaaggagata aatgaagaaa aagaagatga tgaacaaaat aggaaagctt 1020
 tatatgccat ggaaattaaa gttgaaaaag acttgaagac tggagaaagt acagttctgt 1080
 cttccaatac ctctggccat cagatgactt taaaagggtac aggagtaaaa gtttaagatg 1140
 20 atggggcaaaa gtccagtgtt ttcagtaaag tgctaatac aagttggagg t

<210> 52

<211> 1200

<212> DNA

25 <213> Human

<400> 52

30 aacagggact ctactctat caaccccagg ctggagtccg gtgcgcccac cctggctccc 60
 tgcaacctcc gcctcccagg ctcaagcaac tctcctgcct cagtcgctct agtagctggg 120
 actacaggca cacaccacca tgcccagcca atttttgcat tttttgtaga gacagggttt 180
 cgcttcttgt ccaggccggc atcatatact ttaaatacatg cccagatgac tttaatacct 240
 aatacaatat atcaggttgg tttaaaaata attgcttttt tattattttt gcatttttgc 300
 35 accaacctta atgctatgta aatagttggt atactgttg ttaacaacag tatgacaatt 360
 ttggcttttt ctttgtatta ttttgtattt ttttttttta ttgtgtggtc tttttttttt 420
 ttctcagtg tttcaattcc tccttgggtg aatccatgga tgcaaaaccc acagatatga 480
 agggctggct atatatgcat tgatgattgt cctattatat tagttataaa gtgtcattta 540
 atatgtagt aaagttatgg tacagtggaa agagttagttg aaaacataaa catttgacc 600
 40 tttcaagaaa ggtgacttgg tgaagttttt caccttcaaa ctatgtcca gtcagggtc 660
 tgctactaat tagctataat ctttgacaaa attacatcac ctttgagtct cagtgtccct 720
 acctgtaaaa tgaaagaact ggatactctc taaggtcact tccagccctg tcattctata 780
 actctgttat gctgaggaa aaattcacat tgtgttaact gtatgagtc aactgaaaat 840
 gattattaaa gtgggaaaaa gccaattgct tctcttagaa agctcaacta aatttgagaa 900
 45 gaataatctt ttcaattttt taagaattta atatttttta aggttttgac ctatttattt 960
 agagatgggg tctcactctg tcaccagac tggagtacag tggcacaatc atagctcact 1020
 gctgcctcaa attcatgggc tcaagtgatc ctcctgcctc tgctccaga gtagctgcga 1080
 ctatgggcat gtgccaccac gcctggctaa catttgtatt gacctattta tttattgtga 1140
 tttatatctt tttttttttt tctttttttt ttttttcaaa aatcagaaat acttattttt 1200

50 <210> 53

<211> 989

<212> DNA

<213> Human

55 <400> 53

60 aagccaccac tcaaaacttc ctatacattt tcacagcaga gacaagtga catttatttt 60
 tatgcctttc ttctatgtg tatttcaagt ctttttcaaa acaaggcccc aggactctcc 120
 gattcaatta gtccttgggc tggctgactg tgcaggagtc caggagacct ctacaaatgc 180
 agagtgactc tttaccaaca taaaccctag atacatgcaa aaagcaggac ccttcctcca 240
 ggaatgtgcc atttcagatg cacagcacc atgcagaaaa gctggaattt tccttggaa 300
 cgactgtgat agagggtgct acatgaacat tgctactgtc tttctttttt ttgagacag 360
 gtttcgcttg tgcccaggct gagtcaatg cgtgatctca ctactgcaa ttccacctcc 420
 aggttcaagc attctcctgc tcagcctcct agtagctggg ttacaggcac tgccaccatg 480
 65 ccggtcaatt ttgtattttt gtagagatgg atttctccat ttggtcaggc ggtctcgaac 540
 cccaacctca gtgatctgcc acctcagcct cctaagtgtt ggattacagg atgagccacc 600

	cgaccggcca	ctactgtctt	tctttgaccc	ttccagtttc	gaagataaag	aggaaataat	660
	ttctctgaag	tacttgataa	aattttccaaa	caaaacacat	gtccacttca	ctgataaaaa	720
	atttaccgca	gtttggcacc	taagagtatg	acaacagcaa	taaaaagtaa	tttcaaagag	780
	ttaagatttc	ttcagcaaaa	tagatgattc	acatcttcaa	gtcctttttg	aaatcagtta	840
5	ttaatatatt	tctttcctca	tttccatctg	aatgactgca	gcaatagttt	tttttttttt	900
	tttttttttt	ttgcgagatg	gaatctcgct	ctgtcgccca	gcgggagtg	actggcgcaa	960
	gcccggctca	ccgcaatctc	tgccaccgc				
	<210> 54						
10	<211> 250						
	<212> DNA						
	<213> Human						
	<400> 54						
15	catttcccca	ttggctcctga	tggtgaagat	ttagttaaag	aggctgtaag	tcaggttcga	60
	gcagaggcta	ctacaagaag	tagggaatca	agtccctcac	atgggctatt	aaaactaggt	120
	agtgggtgag	tagtgaaaaa	gaaatctgag	caacttcata	acgtaactgc	ctttcagggg	180
	aaagggcatt	cttttaggaac	tgcatctggt	aaccacacac	ttgatccaag	agctagggaa	240
20	acttcagttg						
	<210> 55						
	<211> 2270						
	<212> DNA						
25	<213> Human						
	<400> 55						
	gcgccccga	gcagcgcccg	cgccctccgc	gccttctcgc	ccgggacctc	gagcgaaaga	60
30	ggcccgcgcg	ccgcccagcc	ctcgccctcc	tgcccacccg	gcacaccgcg	ccgccacccc	120
	gaccccgctg	cgcacggcct	gtccgctgca	caccagcttg	ttggcgctct	cgtcgcccg	180
	ctcgcccccg	gctaactcctg	cgcgccacaa	tgagctccc	catcgccagg	gcgctcgct	240
	tagtcgtcac	ccttctccac	ttgaccaggc	tggcgctctc	cacctgcccc	gctgcctgcc	300
	actgccccct	ggaggcgccc	aagtgcgcgc	cgggagtcgg	gctggtcccg	gacggctgcg	360
35	gctgctgtaa	ggctctgcgc	acgagctca	acgaggactg	cagcaaaacg	cagccctgcg	420
	accacaccaa	ggggctggaa	tgcaacttcg	gcgccaagtc	caccgctctg	aaggggatct	480
	gcagagctca	gtcagagggc	agaccctgtg	aataataactc	cagaatctac	caaaacgggg	540
	aaagtttcca	gcccactgt	aaacatcagt	gcacatgtat	tgatggcgcc	gtgggctgca	600
	ttcctctgtg	tccccaagaa	ctatctctcc	ccaacttggg	ctgtcccaac	cctcgctg	660
40	tcaaagttac	cgggcagtg	tgcgaggagt	gggtctgtga	cgaggatagt	atcaaggacc	720
	ccatggagga	ccaggacggc	ctccttgcca	aggagctggg	attcgatgcc	tccgaggtg	780
	agttgacgag	aaacaatgaa	ttgattgcag	ttggaaaagg	cagctcactg	aagcggtccc	840
	ctgttttttg	aatggagcct	cgcacccctt	acaaggccag	aaatgtattg		900
	ttcaaacaac	ttcatggctc	cagtgctcaa	agacctgtgg	aactggatc	tccacacgag	960
45	ttaccaatga	caaccctgag	tgccgccttg	tgaagaaac	ccggatttgt	gaggtgcggc	1020
	cttgtggaca	gccagtgtac	agcagcctga	aaaagggcaa	gaaatgcagc	aagaccaaga	1080
	aatccccga	accagtccag	tttacttacg	ctggatgttt	gagtgtgaag	aaataccggc	1140
	ccaagtactg	cggttcctgc	gtggacggcc	gatgctgcac	gccccagctg	accaggactg	1200
	tgaagatgcg	gttccgctgc	gaagatgggg	agacattttc	caagaacgct	atgatgatcc	1260
50	agtcctgcaa	atgcaactac	aaactgcccgc	atgccaatga	agcagcggtt	cccttctaca	1320
	ggctgttcaa	tgacattcac	aaatttaggg	actaaatgct	acctgggttt	ccagggcaca	1380
	cctagacaaa	caaggagaa	gagtgtcaga	atcagaatca	tgagaaaaat	gggcgggggt	1440
	gggtgtgggtg	atgggactca	ttgtagaaaag	gaagccttgc	tcatttctga	ggagcattaa	1500
	ggatatttca	aactgccaa	ggtgctgggt	cggatggaca	ctaatagcagc	cacgatttga	1560
55	gaatactttg	cttcatagta	ttggagcaca	tgttactgct	tcatttttga	gcttgtggag	1620
	ttgatgactt	tctgttttct	gtttgtaaat	tatttgctaa	gcatattttc	tctaggtttt	1680
	tttctttttg	gggttctaca	gtcgtaaaag	agataataag	attagtttga	cagtttaaag	1740
	cttttattcg	tcctttgaca	aaagtaaagt	ggagggcatt	ccatcccttc	ctgaaggggg	1800
	acactccatg	agtgtctgtg	agaggcagct	atctgcactc	taaactgcaa	acagaaatca	1860
60	ggtgttttaa	gactgaatgt	tttatttatc	aaaatgtagc	ttttggggag	ggaggggaaa	1920
	tgtaatactg	gaataatttg	taaatgattt	taattttata	ttcagtga	agattttatt	1980
	tatggaatta	accattta	aaagaaatat	ttacctaata	tctgagtgtg	tgccattcgg	2040
	tattttttaga	ggtgctccaa	agtcatttag	aacaacctag	ctcacgtact	caattattca	2100
	aacaggactt	attgggatac	agcagtgaat	taagctatta	aaataagata	atgattgctt	2160
65	ttataccttc	agtagagaaa	agtctttgca	tataaagtaa	tgtttaaaaa	acatgtattg	2220
	aacacgacat	tgtatgaagc	acaataaaga	ttctgaagct	aaaaaaaaaa		

<210> 56
 <211> 1636
 <212> DNA
 5 <213> Human

<400> 56

```

10 cttgaatgaa gctgacacca agaaccgcgg gaagagcttg ggcccaaagc aggaaaggga 60
   agcgctcgag ttggaagga accgctgctg ctggccgaac tcaagcccgg gcgccccac 120
   cagtttgatt ggaagtccag ctgtgaaacc tggagcgtcg ccttctcccc agatggctcc 180
   tggtttgctt ggtctcaagg aactgcatc gtcaaactga tccccggcc gttggaggag 240
   cagttcatcc cttaaagggtt tgaagccaaa agccgaagta gcaaaaatga gacgaaagg 300
   cggggcagcc caaaagagaa gacgctggac tgtggtcaga ttgtctggg gctggccttc 360
15 agcccgctggc ctccccacc cagcaggaag ctctgggcac gccaccacc ccaagtggcc 420
   gatgtctctt gcctggttct tgctacggga ctcaacgatg ggcagatcaa gatctgggag 480
   gtgcagacag ggctcctgct tttgaatctt tccggccacc aagatgtcgt gagagatctg 540
   agcttcacac ccagtggcag tttgattttg gtctccgctg cacgggataa gactcttcgc 600
   atctgggacc tgaataaaca cggtaaacag attcaagtgt tatcgggcca cctgcagtgg 660
20 gtttactgct gtcccatctc ccagactgc agcatgctgt gctctgcagc tggagagaag 720
   tcggtctttc tatggagcat gaggtcctac acgttaattc ggaagctaga gggccatcaa 780
   agcagtgttg tctcttgatg cttctcccc gactctgccc tgcttgacac ggcttcttac 840
   gataccaatg tgattatgtg ggaccctac accggcgaaa ggctgaggtc actccaccac 900
   acccagggtg accccgccat ggtgacagt gacgtccaca ttagctcact gagatctgtg 960
25 tgcttctctc cagaaggctt gtaccttgcc acggtggcag atgacagact cctcaggatc 1020
   tggggccctg aactgaaaac tcccattgca tttgctccta tgaccaatgg gctttgctgc 1080
   acattttttc cacatggttg agtcattgcc acagggacaa gagatggcca cgtccagttc 1140
   tggacagctc ctagggtcct gtcctcactg aagcacttat gccggaagc ccttcgaagt 1200
   ttcctaaca cttaccaagt cctagcactg ccaatcccca agaaaatgaa agagtctctc 1260
30 acatacagga ctttttaagc aacaccacat ctgtgcttc tttgtagcag ggtaaatcgt 1320
   cctgtcaaag ggagttgctg gaataatggg ccaaacatct ggtcttgcat tgaaatagca 1380
   tttctttggg attgtgaata gaatgtagca aaaccagatt ccagtgtaca taaaagaatt 1440
   tttttgtctt taaatagata caaatgtcta tcaactttaa tcaagttgta acttatattg 1500
   aagacaattt gatacataat aaaaaattat gacaatgtcc tgggaaaaaa aaaatgtaga 1560
35 aagatgggtg aggggtgggat ggatgaggag cgtggtgacg ggggcctgca gcgggttggg 1620
   gacctgtgc tgcgtt

```

<210> 57
 <211> 460
 40 <212> DNA
 <213> Human

<400> 57

```

45 ccatgtgtgt atgagagaga gagagattgg gagggagagg gagctacta gcgcatatgt 60
   gcctccaggg ggctgcagat gtgtctgagg gtgagccttg tgaaagagaa gacaaaagaa 120
   tggaatgagc taaagcagcc gcctggggtg ggaggccgag cccatttgta tgcagcaggg 180
   ggcaggagcc cagcaaggga ccctccattc ccaggactct ggaggagct gagaccatcc 240
   atgcccgagc agccctccct cacactccat cctgtccagc cctaattgtg cagggtggga 300
50 aactgaggct gggaagtcac atagcaagtg actggcagag ctgggactgg aaccaacca 360
   gcctcctaga ccacggttct tcccatcaat ggaatgctag agactccagc cagggtggga 420
   ccgagctcga attcgtaatc atggtcatag ctgtttcctg

```

<210> 58
 55 <211> 1049
 <212> DNA
 <213> Human

<400> 58

```

60 atctgatcaa gaatacctgc cctggctcact ctgcggatgt ttctgtccac ttgttcacat 60
   tgaggaccaa gatatacctt tttacagagg cacttggttg gtctaacaca gacacctcca 120
   tgacgacatg ctggctcaca ttttgagttt ctgcagaagt cccccccca gcctggacta 180
   cagcagcact ttcccgtagg ggtgcagtag ccgtttcgac agagcctgga gcactctgaa 240
65 gtcagtgtct gtgcagggtg taccgtggct ctgcattcct caggcattaa aggtcttttg 300
   ggatctacaa tttttagtag ttttccattg tgagtctggg tcatactttt actgcttgat 360

```

5 aaaaatgtaaa cttcacctag ttcattcttct ccaaattccca agatgtgacc ggaaaagtag 420
 cctctacagg acccactagt gccgacacag agtgggtttt cttgccactg ctttgtcaca 480
 ggacttttgct ggagagttag gaaattccca ttacgatctc caaacacgta gcttccatac 540
 aatcttttctg actggcagcc ccggtataca aatccacca ccaaaggacc attactgaat 600
 ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccctttat tatctgtaga 660
 attctggctg atgatctgtt tttccattg gagtctgaac acagtatcgt taaattgatg 720
 tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780
 aacacttcgg ggggctggtt ggtgctgttg aagtgtgggt tgctccttgg tatggaataa 840
 ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900
 10 aacccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960
 aaaaacccgt cagggccaaa gagcagttgc cctcccagat gctttctgtg gagttctgca 1020
 acttcaagaa agactctggc tgttctcaa

<210> 59
 15 <211> 747
 <212> DNA
 <213> Human

20 <400> 59

25 tttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaaacgtc 60
 ccttaattta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120
 cttaaatata atgtatcata ccaaccacag taaaccaagt acaaaaaata ttcatataaa 180
 gttgttcaca cgtaggtcct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240
 atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaac ctccctcacg 300
 ctgctctgtc ccacacaaat gtttaagaag tcaactgcaat gtactccccg gctctgatga 360
 aaagaagccc ctggcacaaa agattccagt gccctgaag aggctccctt cctcctgtgg 420
 gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480
 ccctcgggca ggcaacggca gtggactcat ctcggtgatg gctgtagatg ctaacactgg 540
 30 ccaattcaat gccacaccta ctggttacct tttgagggca tttctccaga cagaagcccc 600
 ttgaagccta ggtagggcag gatcagagat acaccggtgt ttgtctcgaa gggtccaca 660
 gccagtagc acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720
 cgcgaattta gtagtaatag cggccgc

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.